Chimeric switch receptors for converting immunosuppressive signals into co-stimulatory signals
By designing chimeric switch receptors, the activity and efficacy of CAR-T cells in the immunosuppressive tumor microenvironment is enhanced, and the problem of insufficient efficiency and safety of existing CAR-T cell therapies in this environment is solved, and the problem of insufficient efficiency and safety of existing CAR-T cell therapies in this environment is achieved. More efficient target cell recognition and killing.
Patent Information
- Application Number
- CN202380030493.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-22
- Filing Date
- 2023-03-29
- Publication Date
- 2024-11-12
AI Technical Summary
Existing CAR-T cell therapies are insufficient in efficiency and safety in the face of the immunosuppressive tumor microenvironment, making it difficult to effectively identify and kill target cells.
A chimeric polypeptide called a chimeric switch receptor is designed that fuses the transmembrane domain and the intracellular signaling domain, which can be activated in an immunosuppressive environment, enhances the activity of CAR-T cells, and in the Keep activity low in other environments to ensure safety.
Through chimeric switch receptors, CAR-T cells enhance their activity and potency in the immunosuppressive tumor microenvironment, secrete acceptable levels of cytokines, improving the safety and effectiveness of the therapy.
Smart Images

Figure BDA0005060183780000311 
Figure BDA0005060183780000401 
Figure BDA0005060183780000411
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of priority to U.S. Provisional Application No. 63 / 325,069, filed on March 29, 2022, and U.S. Provisional Application No. 63 / 453,936, filed on March 22, 2023, the contents of which are hereby incorporated by reference in their entirety.
[0003] Sequence Listing
[0004] This application contains a sequence listing, which is submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy was created on March 24, 2023, named AT-050_03_SL.xml, and is 294,461 bytes in size. Technical Field
[0005] The present disclosure generally relates to chimeric polypeptides, engineered immune cells (eg, T cells) comprising the same, polynucleotides encoding the same, and uses of the engineered immune cells in therapeutic applications. Background Art
[0006] Adoptive transfer of immune cells genetically modified to recognize malignant tumor-associated antigens has shown promise as a new approach to treating cancer (see, e.g., Brenner et al., Current Opinion in Immunology, 22(2):251-257 (2010); Rosenberg et al., Nature Reviews Cancer, 8(4):299-308 (2008)). Immune cells can be genetically modified to express chimeric antigen receptors (CARs), i.e., fusion proteins comprising an antigen recognition portion and a T cell activation domain (see, e.g., Eshhar et al., Proc. Natl. Acad. Sci. USA, 90(2):720-724 (1993)). Immune cells containing CARs, such as CAR-T cells (CAR-T), are engineered to confer antigen specificity while maintaining or enhancing their ability to recognize and kill target cells.
[0007] Improvements in CAR-T cell therapy, such as increased efficiency and / or accuracy of treatment, would benefit this patient population. Summary of the invention
[0008] In particular, provided herein are chimeric polypeptides, particularly chimeric switch receptors, which are fusion proteins comprising an extracellular domain and / or a transmembrane domain derived from an inhibitory receptor (e.g., PD1 or TGFbR2 (TGFβ receptor II)) fused to a transmembrane domain and / or an intracellular signaling domain derived from one or more co-stimulatory proteins (e.g., CD2, CD28, MyD88, DAP10 or ICOS).
[0009] Chimeric switch receptors can be used in cell-based immunotherapy (e.g., CAR T therapy) by destroying immunosuppression and enhancing efficacy. The benefits of chimeric switch receptors are multifaceted. First, the extracellular domain can be used as a decoy / dominant negative receptor, which protects CAR T cells from immunosuppression (e.g., PD1 ligand PDL1 or TGFb). Secondly, the intracellular signaling domain provides additional co-stimulatory signals, which can enhance CAR T cell activity and efficacy. Third, signaling by the chimeric switch receptor is activated in the presence of an extracellular domain ligand. Therefore, it can be preferentially turned on in an inhibitory tumor microenvironment (e.g., where the extracellular domain ligand is rich) where enhanced efficacy is most needed, and turned off or closed in other places (e.g., in an environment with little or no extracellular domain ligand) to maintain adequate safety. In certain embodiments, engineered immune cells comprising or expressing the chimeric polypeptide disclosed herein overcome the immunosuppressive tumor microenvironment, showing enhanced activity, while secreting acceptable levels of cytokines and achieving adequate or improved safety.
[0010] Also provided herein are polynucleotides and vectors encoding the disclosed chimeric switch receptors, cells (e.g., engineered immune cells, such as engineered T cells) comprising and / or expressing the disclosed chimeric switch receptors and / or polynucleotides and vectors encoding the same, populations of such cells, compositions comprising such cells and cell populations, methods of treating disorders (e.g., cancer) comprising administering the cells and cell populations disclosed herein, methods of engineering such cells, and cells made by such methods.
[0011] In one aspect, the present disclosure provides a polynucleotide encoding a chimeric polypeptide comprising an extracellular domain, a transmembrane domain, and one or more intracellular domains, wherein the extracellular domain comprises the extracellular domain of an inhibitory protein. In some embodiments, the inhibitory protein is an inhibitory receptor. In some embodiments, the extracellular domain of the encoded chimeric polypeptide comprises a PD-1 (programmed cell death protein-1) extracellular domain. In some embodiments, the PD-1 extracellular domain comprises the amino acid sequence of a wild-type hPD-1 (human PD-1) extracellular domain (e.g., the amino acid sequence of SEQ ID NO: 9). In some embodiments, the PD-1 extracellular domain comprises the amino acid sequence of a variant of the wild-type hPD-1 extracellular domain (e.g., the amino acid sequence of a variant of SEQ ID NO: 9, such as an amino acid sequence having at least 90% identity with SEQ ID NO: 9). In some embodiments, the PD-1 extracellular domain variant comprises one or more amino acid insertions, deletions, and / or substitutions relative to the wild-type PD-1 extracellular domain (e.g., relative to SEQ ID NO: 9). In some embodiments, the encoded PD-1 extracellular domain variant of the chimeric polypeptide comprises the amino acid sequence of a high affinity ("HA") hPD-1 extracellular domain (e.g., an exemplary HA hPD-1 extracellular domain comprises or has the amino acid sequence of SEQ ID NO: 10; for HA hPD-1 proteins, see, e.g., RL Maute et al., Proc Natl Acad Sci US A. 2015; 112(47):E6506-E6514. Doi: 10.1073 / pnas.1519623112).
[0012] In some embodiments of the polypeptides and encoded polypeptides disclosed herein, wherein the second amino acid sequence is at least 90% identical to the first amino acid sequence, one or more (e.g., all or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acids in the second amino acid sequence are different from the corresponding amino acids in the first amino acid sequence, such as amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.
[0013] In some embodiments, the extracellular domain of the encoded chimeric polypeptide comprises a TGFβ receptor (e.g., TGFBR2) extracellular domain. In some embodiments, the TGFβ receptor extracellular domain comprises the amino acid sequence of the wild-type hTGFb receptor extracellular domain (e.g., the amino acid sequence of SEQ ID NO: 12). In some embodiments, the extracellular domain of the encoded chimeric polypeptide comprises a variant of the TGFβ receptor (e.g., TGFBR2) extracellular domain. In some embodiments, the extracellular domain of the encoded chimeric polypeptide comprises a variant of the amino acid sequence of SEQ ID NO: 12, such as an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 12). In some embodiments, the extracellular domain comprises an hTGFb receptor extracellular domain variant, which comprises one or more amino acid insertions, deletions and / or substitutions relative to the wild-type hTGFb receptor extracellular domain (e.g., relative to SEQ ID NO: 12). In some embodiments, the variant comprises a deletion of 25 amino acids from the N-terminus of the mature wild-type hTGFb receptor and comprises the amino acid sequence of SEQ ID NO:13.
[0014] In some embodiments, the extracellular domain of the encoded chimeric polypeptide comprises an antibody or an antigen binding portion of an antibody that specifically recognizes and binds to an inhibitory ligand (e.g., an inhibitory ligand such as PDL1 or TGFβ or one or more specific TGFβ isoforms). In some embodiments, the extracellular domain of the encoded chimeric polypeptide comprises a single-chain variable fragment (scFv) that specifically recognizes and binds to an inhibitory ligand (such as PDL1 or TGFβ or one or more TGFβ isoforms, for example, a TGFβ isoform selected from TGFβ1, TGFβ2, or TGFβ3). In some embodiments, the extracellular domain of the encoded chimeric polypeptide comprises an anti-PDL1 scFv. In some embodiments, the anti-PDL1 scFv may comprise, for example, an antigen binding domain of avelumab, durvalumab, or atezolizumab. In some embodiments, the extracellular domain of the encoded chimeric polypeptide comprises an anti-TGFβ scFv. In some embodiments, the extracellular domain of the encoded chimeric polypeptide comprises an anti-TGFβscFv that binds and recognizes only one TGFβ isoform (such as a TGFβ isoform selected from TGFβ1, TGFβ2, or TGFβ3), for example, an anti-TGFβscFv that binds and recognizes only TGFβ1. In some embodiments, the anti-TGFb scFv may comprise an antigen binding domain of non-sumetumomab or SAR438459. Anti-TGFβ isoform antibodies (e.g., anti-TGFβ isoform scFv) and methods for preparing the same are disclosed in, for example, US20190071493, which is incorporated herein by reference in its entirety.
[0015] In some embodiments, the encoded polypeptide comprises one or only one intracellular signaling domain. In some embodiments, the encoded polypeptide comprises more than one intracellular signaling domain. In some embodiments, the encoded polypeptide comprises more than one intracellular signaling domain, all of which are identical to one another. In some embodiments, the encoded polypeptide comprises more than one intracellular signaling domain, all of which are different from one another. In some embodiments, the encoded polypeptide comprises more than one intracellular signaling domain, some of which are identical to one another and some of which are different from others. In some embodiments, the encoded polypeptide comprises two, three, four, five, or six intracellular signaling domains, all of which are identical to one another, all of which are different from one another, or some of which are identical to one another.
[0016] In some embodiments, the one or more intracellular domains of the encoded chimeric polypeptide comprise one or more intracellular signaling domains. In some embodiments, the one or more intracellular signaling domains are selected from the group consisting of a CD28 intracellular signaling domain, a CD2 intracellular signaling domain, a MyD88 intracellular signaling domain, an ICOS intracellular signaling domain, a DAP10 intracellular signaling domain, an OX40 intracellular signaling domain, a BAFFR intracellular signaling domain, and a CD40 intracellular signaling domain, any variants thereof, and any combination thereof. In some embodiments, the one or more intracellular signaling domains comprise a CD28 intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise a CD2 intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise a MyD88 intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise an ICOS intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise a DAP10 intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise an OX40 intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise a BAFFR intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise a CD40 intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise any combination of CD28, CD2, MyD88, ICOS, DAP10, OX40, BAFFR, and CD40 intracellular signaling domains.
[0017] In some embodiments, one or more intracellular domains of the encoded chimeric polypeptide comprises an amino acid sequence or two or more copies of an amino acid sequence of any one or more than one of SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 15, SEQ ID NO: 29, SEQ ID NO: 27, SEQ ID NO: 33, SEQ ID NO: 31, and SEQ ID NO: 35 (shown in Table 1). The corresponding polynucleotide sequences are shown in Table 2. In some embodiments, one or more intracellular domains of the encoded chimeric polypeptide comprises any combination of the amino acid sequences of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, and SEQ ID NO: 35 (as shown in Table 1) (e.g., any two, any three, any four, or any five thereof, or multiple copies of any two, any three, any four, or any five thereof). The corresponding polynucleotide sequences are shown in Table 2.
[0018] In some embodiments, the transmembrane domain of the encoded chimeric polypeptide comprises a CD28 transmembrane domain, a CD2 transmembrane domain, a PD-1 transmembrane domain, an ICOS transmembrane domain, a DAP10 transmembrane domain, an OX40 transmembrane domain, a BAFFR transmembrane domain, or a CD40 transmembrane domain. In some embodiments, the transmembrane domain of the encoded chimeric polypeptide comprises an amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 17, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, or SEQ ID NO: 34 (shown in Table 1). The corresponding polynucleotide sequences are shown in Table 2.
[0019] In some embodiments, the intracellular domain of the encoded chimeric polypeptide or chimeric switch receptor comprises a CD28 or CD2 intracellular domain or a variant thereof. In some embodiments, the intracellular domain comprises an amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 24. In some embodiments, the chimeric polypeptide comprises a variant CD28 or variant CD2 intracellular domain, and the engineered immune cells comprising or expressing the chimeric polypeptide express or secrete reduced levels of cytokines after the extracellular domain of the chimeric polypeptide binds to its ligand. In some embodiments, the intracellular domain comprises a variant CD28 or variant CD2 intracellular domain, and the reduced level of cytokines is about 1.5 times, 2 times, 2.5 times, 3 times, 3.5 times, 4 times, 4.5 times and 5 times lower than the level of cytokines secreted by engineered immune cells comprising or expressing a chimeric polypeptide containing a corresponding wild-type intracellular domain. In certain embodiments, the extracellular domain comprises a PD1 or TGFb receptor extracellular domain. In some embodiments, the cytokine is GM-CSF, INFg, TNFa or IL2. In some embodiments, the engineered immune cells comprising or expressing the chimeric polypeptide of the present disclosure secrete reduced levels of cytokines and exhibit improved safety when used for adoptive cell therapy. In some embodiments, the engineered immune cells are CAR T cells.
[0020] In some embodiments, the intracellular domain of the encoded chimeric polypeptide comprises a CD2 intracellular domain or a variant thereof. In some embodiments, the intracellular domain of the encoded chimeric polypeptide comprises a CD2 intracellular domain or a variant thereof, and the transmembrane domain of the encoded chimeric polypeptide comprises a CD2 transmembrane domain. In some embodiments, the intracellular domain of the encoded chimeric polypeptide comprises a CD2 intracellular domain having an amino acid sequence of SEQ ID NO: 23. In some embodiments, the intracellular domain of the encoded chimeric polypeptide comprises an amino acid sequence having at least about 90% identity to the amino acid sequence of SEQ ID NO: 23.
[0021] In some embodiments of the polynucleotides encoding chimeric polypeptides comprising an extracellular domain, a transmembrane domain, and one or more intracellular domains disclosed herein, the intracellular domain comprises a truncated CD2 intracellular domain. In some embodiments, the truncated CD2 intracellular domain comprises the amino acid sequence of SEQ ID NO: 24. In some embodiments, the truncated CD2 intracellular domain comprises an amino acid sequence having at least about 90% identity to the amino acid sequence of SEQ ID NO: 24.
[0022] In some embodiments of the polynucleotides disclosed herein, the encoded transmembrane domain comprises a CD2 transmembrane domain. In some embodiments, the CD2 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 22. In some embodiments, the CD2 transmembrane domain comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 22.
[0023] In some embodiments of the polynucleotides disclosed herein, the encoded polypeptide comprises a signal peptide. In some embodiments, the encoded polypeptide comprises a CD8α signal peptide. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 1. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 2.
[0024] In some embodiments of the polynucleotides encoding chimeric polypeptides comprising an extracellular domain, a transmembrane domain, and one or more intracellular domains disclosed herein, the polypeptide further comprises a hinge domain located between the extracellular domain and the transmembrane domain. In some embodiments, the hinge domain comprises the amino acid sequence of SEQ ID NO: 36. In some embodiments, the hinge domain comprises an amino acid sequence having at least about 90% identity to the amino acid sequence of SEQ ID NO: 36.
[0025] In some embodiments of polynucleotides encoding chimeric polypeptides (e.g., chimeric switch receptors) comprising an extracellular domain, a transmembrane domain, and one or more intracellular domains disclosed herein, the polynucleotide comprises a nucleic acid sequence of any one of SEQ ID NOs: 118-158 (shown in Table 4), and the polypeptide comprises an amino acid sequence of any one of SEQ ID NOs: 75-115 (shown in Table 3). In some embodiments, the polypeptide comprises an amino acid sequence having at least 90% identity to an amino acid sequence of any one of SEQ ID NOs: 75-115. In some embodiments, the encoded polypeptide is a PD1 chimeric switch receptor and comprises an amino acid sequence of any one of SEQ ID NOs: 75-94. In some embodiments, the encoded polypeptide comprises an amino acid sequence having at least 90% identity to an amino acid sequence of any one of SEQ ID NOs: 75-94. In some embodiments, the encoded polypeptide comprises an amino acid sequence having at least 90% identity to an amino acid sequence of any one of SEQ ID NOs: 75-94. In some embodiments, the encoded polypeptide is a TGF-βR2 (TGFBR2 or BR2) chimeric switch receptor and comprises an amino acid sequence of any one of SEQ ID NOs: 95-115. In some embodiments, the encoded polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence of any one of SEQ ID NOs: 95-115. In some embodiments, the encoded polypeptide further comprises a signal peptide. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 1. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 2.
[0026] In some embodiments of the polynucleotides of the chimeric polypeptides disclosed herein that encode an extracellular domain, a transmembrane domain, and one or more intracellular domains, the chimeric polypeptide is a first polypeptide, and the polynucleotide further encodes a second polypeptide. In some embodiments, the second polypeptide comprises or is a chimeric cytokine receptor (CCR). In some embodiments, CCR has constitutive activity. In some embodiments, CCR is inducible. In some embodiments, the second polypeptide comprises or is a chimeric antigen receptor (CAR).
[0027] In another aspect, the present disclosure provides a vector comprising a polynucleotide disclosed herein, e.g., a polynucleotide encoding a chimeric polypeptide comprising an extracellular domain, a transmembrane domain, and one or more intracellular domains. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a lentiviral vector or an adenoviral vector.
[0028] In another aspect, the present disclosure provides a chimeric polypeptide encoded by a polynucleotide disclosed herein. In yet another aspect, the present disclosure provides a chimeric polypeptide encoded by a vector disclosed herein.
[0029] In another aspect, the present disclosure provides a chimeric polypeptide comprising an extracellular domain, a transmembrane domain, and one or more intracellular domains, wherein the extracellular domain comprises an extracellular domain of an inhibitory protein, such as an inhibitory receptor, for example, an extracellular domain of an inhibitory transmembrane receptor. In some embodiments, the extracellular domain of the chimeric polypeptide comprises a PD-1 extracellular domain. In some embodiments, the PD-1 extracellular domain comprises an amino acid sequence of a wild-type hPD-1 extracellular domain (e.g., an amino acid sequence of SEQ ID NO: 9). In some embodiments, the PD-1 extracellular domain comprises an amino acid sequence of a variant of a wild-type hPD-1 extracellular domain (e.g., an amino acid sequence of a variant of SEQ ID NO: 9, such as an amino acid sequence having at least 90% identity with SEQ ID NO: 9). In some embodiments, the PD-1 extracellular domain variant comprises one or more amino acid insertions, deletions, and / or substitutions relative to the wild-type PD-1 extracellular domain (e.g., relative to SEQ ID NO: 9). In some embodiments, the PD-1 extracellular domain variant of the chimeric polypeptide comprises the amino acid sequence of a high affinity ("HA") hPD-1 extracellular domain (eg, comprising or having the amino acid sequence of SEQ ID NO: 10).
[0030] In some embodiments, the extracellular domain of the chimeric polypeptide comprises a TGFβ receptor (e.g., TGFBR2) extracellular domain. In some embodiments, the TGFβ receptor extracellular domain comprises the amino acid sequence of the wild-type hTGFb receptor extracellular domain (e.g., the amino acid sequence of SEQ ID NO: 12). In some embodiments, the extracellular domain of the chimeric polypeptide comprises a variant of the TGFβ receptor (e.g., TGFBR2) extracellular domain. In some embodiments, the extracellular domain of the chimeric polypeptide comprises a variant of the amino acid sequence of SEQ ID NO: 12, such as an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 12). In some embodiments, the extracellular domain comprises an hTGFb receptor extracellular domain variant, which comprises one or more amino acid insertions, deletions and / or substitutions relative to the wild-type hTGFb receptor extracellular domain (e.g., relative to SEQ ID NO: 12). In some embodiments, the variant comprises a 25 amino acid deletion and comprises the amino acid sequence of SEQ ID NO: 13 (TGFβR2 ECDΔN25, also referred to herein as TGFβR2 ECD dN25).
[0031] In some embodiments, the extracellular domain of the chimeric polypeptide comprises an antibody or an antigen binding portion of an antibody that specifically recognizes and binds to an inhibitory ligand, such as PDL1 or TGFβ or one or more specific TGFβ isoforms. In some embodiments, the extracellular domain of the chimeric polypeptide comprises a single-chain variable fragment (scFv) that specifically recognizes and binds to an inhibitory ligand, such as PDL1 or TGFβ or one or more TGFβ isoforms, for example, a TGFβ isoform selected from TGFβ1, TGFβ2 or TGFβ3. In some embodiments, the extracellular domain of the chimeric polypeptide comprises an anti-PDL1 scFv. In some embodiments, the extracellular domain of the chimeric polypeptide comprises an anti-TGFβ scFv. In some embodiments, the extracellular domain of the chimeric polypeptide comprises an anti-TGFβscFv that binds and recognizes only one TGFβ isoform (such as a TGFβ isoform selected from TGFβ1, TGFβ2, or TGFβ3), for example, an anti-TGFβscFv that binds and recognizes only TGFβ1. Anti-TGFβ isoform antibodies (e.g., anti-TGFβ isoform scFv) and methods for preparing the same are disclosed in, for example, US20190071493, which is incorporated herein by reference in its entirety.
[0032] In some embodiments, the chimeric polypeptides provided herein comprise one or only one intracellular signaling domain. In some embodiments, the chimeric polypeptide comprises more than one intracellular signaling domain. In some embodiments, the chimeric polypeptide comprises more than one intracellular signaling domain, all of which are identical to one another. In some embodiments, the chimeric polypeptide comprises more than one intracellular signaling domain, all of which are different from one another. In some embodiments, the chimeric polypeptide comprises more than one intracellular signaling domain, some of which are identical to one another and some of which are different from others. In some embodiments, the chimeric polypeptide comprises two, three, four, five or six intracellular signaling domains, all of which are identical to one another, all of which are different from one another, or some of which are identical to one another.
[0033] In some embodiments, one or more intracellular domains of the chimeric polypeptides provided herein comprise one or more intracellular signaling domains. In some embodiments, one or more intracellular signaling domains are selected from the group consisting of a CD28 intracellular signaling domain, a CD2 intracellular signaling domain, a MyD88 intracellular signaling domain, an ICOS intracellular signaling domain, a DAP10 intracellular signaling domain, an OX40 intracellular signaling domain, a BAFFR intracellular signaling domain, and a CD40 intracellular signaling domain, and any combination thereof. In some embodiments, one or more intracellular signaling domains comprise a CD28 intracellular signaling domain. In some embodiments, one or more intracellular signaling domains comprise a CD2 intracellular signaling domain. In some embodiments, one or more intracellular signaling domains comprise a MyD88 intracellular signaling domain. In some embodiments, one or more intracellular signaling domains comprise an ICOS intracellular signaling domain. In some embodiments, one or more intracellular signaling domains comprise a DAP10 intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise an OX40 intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise a BAFFR intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise a CD40 intracellular signaling domain. In some embodiments, the one or more intracellular signaling domains comprise any combination of CD28, CD2, MyD88, ICOS, DAP10, OX40, BAFFR, and CD40 intracellular signaling domains.
[0034] In some embodiments, one or more intracellular domains of a chimeric polypeptide of the present disclosure comprises an amino acid sequence or two or more copies of an amino acid sequence of any one or more than one of SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 15, SEQ ID NO: 29, SEQ ID NO: 27, SEQ ID NO: 33, SEQ ID NO: 31, and SEQ ID NO: 35. In some embodiments, one or more intracellular domains of a chimeric polypeptide of the present disclosure comprises any combination of the amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 15, SEQ ID NO: 29, SEQ ID NO: 27, SEQ ID NO: 33, SEQ ID NO: 31, and SEQ ID NO: 35 (e.g., any two, any three, any four, or any five thereof, or multiple copies of any two, any three, any four, or any five thereof).
[0035] In some embodiments, the intracellular domain comprises a CD2 intracellular domain or a variant thereof. In some embodiments, the intracellular domain comprises a variant CD2 intracellular domain, wherein the intracellular domain comprises at least one SH3 domain and / or at least one GYF binding domain, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain. In some embodiments, the SH3 domain comprises an amino acid sequence of SEQ ID NO: 168 or 169, and the GYF binding domain comprises an amino acid sequence of SEQ ID NO: 176, in some embodiments, the intracellular domain comprises SEQ ID NO: 170, 171, 172, 173, 174, 175 and 176 at least one, at least two, at least three, at least four, at least five, at least six or all of the amino acid sequence, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain. In some embodiments, the intracellular domain comprises a variant CD2 intracellular domain, the variant CD2 intracellular domain comprises SEQ ID NO: 170 and 176, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain. In some embodiments, the intracellular domain comprises a variant CD2 intracellular domain, the variant CD2 intracellular domain comprises SEQ ID NO: 174 and 175, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain. In some embodiments, the intracellular domain comprises a variant CD2 intracellular domain, the variant CD2 intracellular domain comprises SEQ ID NO: 170, 171, 173, 174 and 175, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain. In some embodiments, the intracellular domain comprises a variant of a CD2 intracellular domain, the variant comprising SEQ ID NO: 170-176, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain. In some embodiments, the truncated CD2 intracellular domain comprises at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 amino acid deletions from a full-length CD2 intracellular domain, and optionally the truncated CD2 intracellular domain comprises one or more GYF binding domains and / or one or more SH3 domains. In some embodiments, the full-length CD2 intracellular domain comprises the amino acid sequence of SEQ ID NO: 23.
[0036] In some embodiments, the intracellular domain of the chimeric polypeptide of the present disclosure comprises a CD2 intracellular domain or a variant thereof. In some embodiments, the intracellular domain of the chimeric polypeptide of the present disclosure comprises a CD2 intracellular domain or a variant thereof, and the transmembrane domain of the chimeric polypeptide comprises a CD2 transmembrane domain. In some embodiments, the intracellular domain of the chimeric polypeptide of the present disclosure comprises a CD2 intracellular domain having an amino acid sequence of SEQ ID NO: 23. In some embodiments, the intracellular domain of the encoded chimeric polypeptide comprises an amino acid sequence having at least about 90% identity to the amino acid sequence of SEQ ID NO: 23.
[0037] In some embodiments of the chimeric polypeptides disclosed herein, the extracellular domain comprises a truncated CD2 intracellular domain. In some embodiments, the truncated CD2 intracellular domain comprises the amino acid sequence of SEQ ID NO: 24. In some embodiments, the truncated CD2 intracellular domain comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 24.
[0038] In some embodiments, the transmembrane domain of the chimeric polypeptide of the present disclosure includes a CD28 transmembrane domain, a CD2 transmembrane domain, a PD-1 transmembrane domain, an ICOS transmembrane domain, a DAP10 transmembrane domain, an OX40 transmembrane domain, a BAFFR transmembrane domain or a CD40 transmembrane domain. In some embodiments, the transmembrane domain of the chimeric polypeptide of the present disclosure comprises an amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32 or SEQ ID NO: 34.
[0039] In some embodiments, the transmembrane domain optionally comprises the amino acid residues of an adjacent extracellular domain. In some embodiments, the transmembrane domain optionally comprises 1-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3 or 1-2 amino acid residues of an adjacent extracellular domain.
[0040] In some embodiments of the chimeric polypeptides disclosed herein, the transmembrane domain comprises a CD2 transmembrane domain. In some embodiments, the CD2 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 22. In some embodiments, the CD2 transmembrane domain comprises an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO: 22.
[0041] In some embodiments, the chimeric polypeptide comprises a PD1 extracellular domain comprising an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 9 or SEQ ID NO: 10. In some embodiments, the chimeric polypeptide comprises a CD28 transmembrane domain comprising an amino acid sequence that is at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 17. In some embodiments, the chimeric polypeptide comprises a CD28 intracellular domain that is at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to SEQ ID NO: 19. In some embodiments, the chimeric polypeptide comprises a CD2 transmembrane domain comprising an amino acid sequence having at least about 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 22. In some embodiments, the chimeric polypeptide comprises a CD2 intracellular domain comprising an amino acid sequence having at least about 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 24. In some embodiments, the chimeric polypeptide comprises an amino acid sequence having at least about 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 76, 79, 85, or 88.
[0042] In some embodiments of the chimeric polypeptides disclosed herein, the chimeric polypeptide comprises a signal peptide. In some embodiments, the signal peptide comprises a CD8α signal peptide. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 1. In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 2.
[0043] In some embodiments of the chimeric polypeptides disclosed herein, the polypeptide further comprises a hinge domain located between the extracellular domain and the transmembrane domain. In some embodiments, the hinge domain comprises the amino acid sequence of SEQ ID NO: 36. In some embodiments, the hinge domain comprises an amino acid sequence having at least about 90% identity to the amino acid sequence of SEQ ID NO: 36.
[0044] In some embodiments of the chimeric polypeptides disclosed herein, the chimeric polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 75- 115. In some embodiments, the polypeptide comprises an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 75-115.
[0045] On the other hand, the present disclosure provides a kind of engineered cell, for example, an engineered immune cell comprising a polynucleotide encoding a chimeric polypeptide disclosed herein. In some embodiments, an engineered cell (e.g., an engineered immune cell) expresses an encoded chimeric polypeptide, for example, an engineered immune cell functionally expresses an encoded chimeric polypeptide, for example, on a cell surface. In some embodiments, an engineered immune cell functionally expresses a chimeric polypeptide comprising a signal peptide, the signal peptide of the chimeric polypeptide is cut, and the chimeric polypeptide lacking the signal peptide is expressed on the surface of the engineered immune cell. In some embodiments, an engineered immune cell comprises and / or expresses a chimeric polypeptide without its signal peptide, for example, on the surface of an engineered immune cell. In some embodiments, an engineered cell (e.g., an engineered immune cell) comprising a polynucleotide encoding a chimeric polypeptide disclosed herein does not express a chimeric polypeptide.
[0046] On the other hand, the present disclosure provides an engineered immune cell comprising a vector disclosed herein containing a polynucleotide disclosed herein. In some embodiments, an engineered cell (e.g., an engineered immune cell) expresses an encoded chimeric polypeptide, for example, an engineered immune cell functionally expresses an encoded chimeric polypeptide, for example, on a cell surface. In some embodiments, an engineered immune cell functionally expresses a chimeric polypeptide comprising a signal peptide, and the signal peptide of the chimeric polypeptide is cut, and the chimeric polypeptide lacking the signal peptide is expressed on the surface of the engineered immune cell. In some embodiments, an engineered immune cell comprises and / or expresses a chimeric polypeptide without a signal peptide, for example, on the surface of an engineered immune cell. In some embodiments, an engineered cell (e.g., an engineered immune cell) comprising a polynucleotide encoding a chimeric polypeptide disclosed herein does not express a chimeric polypeptide.
[0047] In another aspect, the present disclosure provides an engineered immune cell comprising a chimeric polypeptide disclosed herein. In some embodiments, the engineered immune cell comprises a chimeric polypeptide. In some embodiments, the engineered immune cell comprises a chimeric polypeptide lacking a signal peptide.
[0048] In another aspect, the present disclosure provides an engineered immune cell that expresses a chimeric polypeptide disclosed herein. In some embodiments, the engineered immune cell comprises a chimeric polypeptide. In some embodiments, the engineered immune cell comprises a chimeric polypeptide lacking a signal peptide.
[0049] In some embodiments, the engineered immune cell comprises or expresses a chimeric polypeptide of the present disclosure, which comprises a CD28 or CD2 intracellular domain or a variant thereof. In some embodiments, the intracellular domain comprises an amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 20 or SEQ ID NO: 24. In some embodiments, the chimeric polypeptide comprises a variant CD28 or variant CD2 intracellular domain, and the engineered immune cell expresses or secretes a reduced level of cytokines after the extracellular domain of the chimeric polypeptide binds to its ligand. In some embodiments, the reduced level of cytokines is about 1.5 times, 2 times, 2.5 times, 3 times, 3.5 times, 4 times, 4.5 times and 5 times lower than the level of cytokines secreted by engineered immune cells comprising or expressing a chimeric polypeptide containing a corresponding wild-type intracellular domain. In certain embodiments, the extracellular domain comprises a PD1 or TGFb receptor extracellular domain. In some embodiments, the cytokine is GM-CSF, INFg, TNFa or IL2. In some embodiments, the engineered immune cells of the present disclosure comprising or expressing chimeric polypeptides secrete reduced levels of cytokines and exhibit acceptable or improved safety when used for adoptive cell therapy. In some embodiments, the engineered immune cells are CAR T cells.
[0050] On the other hand, the engineered immune cells disclosed herein further comprise and / or express a chimeric antigen receptor (CAR), wherein CAR comprises an extracellular ligand binding domain, a transmembrane domain, and an intracellular signaling domain. In some embodiments, the engineered immune cells comprise a polynucleotide or vector encoding CAR. In some embodiments, the CAR intracellular signaling domain comprises a copy or more than one copy of any one or more of a CD3ζ signaling domain, a CD28 signaling domain, and a 4-1BB signaling domain. In some embodiments, CAR comprises an extracellular ligand binding domain that specifically recognizes and / or binds to DLL3, for example, a DLL3CAR described and disclosed in WO 2020 / 180591. In some embodiments, CAR comprises the amino acid sequence of SEQ ID NO:73 shown in Table 3, which comprises components rituximab mimetic epitope, 2G1 scFv (specifically recognizes and binds to DLL3), rituximab mimetic epitope, CD8α hinge, CD8α transmembrane, CD8α cytoplasmic domain (truncated), 4-1BB (TNFRSF9, CD137) cytoplasmic domain and CD3ζ cytoplasmic domain. In some embodiments, CAR comprises the following components: rituximab mimetic epitope, 2G1 scFv (specifically recognizes and binds to DLL3), rituximab mimetic epitope, CD8α hinge, CD8α transmembrane, CD8α cytoplasmic domain (truncated), 4-1BB (TNFRSF9, CD137) cytoplasmic domain and CD3ζ cytoplasmic domain. In some embodiments, CAR comprises an amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:116. In some embodiments, the CAR amino acid sequence is an amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO: 116. In some embodiments, the CAR is encoded by the nucleic acid sequence of SEQ ID NO: 116 shown in Table 4.
[0051] On the other hand, the engineered immune cell disclosed herein further includes and / or expresses a chimeric cytokine receptor (CCR). In some embodiments, CCR is an inducible CCR. In some embodiments, CCR is a constitutively active CCR (CACCR). CCR is disclosed and described in, for example, WO2019169290, WO2020180694, WO2020180664, and WO2021041806, and each of these patents is hereby incorporated by reference as a whole. In some embodiments, CCR is a CCR disclosed and / or described in any one of WO2019169290, WO2020180694, WO2020180664, and WO2021041806. In some embodiments, the engineered immune cell includes a polynucleotide or a vector encoding CCR (e.g., inducible CCR or CACCR). In some embodiments, the engineered immune cell comprises a polynucleotide or vector encoding CCR, which comprises an amino acid sequence of SEQ ID NO: 162. In some embodiments, CCR further comprises a signal peptide. In some embodiments, the signal peptide comprises an amino acid sequence of SEQ ID NO: 1. In some embodiments of engineered cells (e.g., engineered immune cells disclosed herein), the cell comprises: a first polynucleotide or vector encoding a chimeric polypeptide disclosed herein (e.g., a chimeric switch receptor), a second polynucleotide or vector encoding CAR (e.g., DLL3 CAR), and a third polynucleotide or vector encoding CCR. In some embodiments of engineered cells (e.g., engineered immune cells disclosed herein), the cell comprises: a first polynucleotide or vector encoding any two of a chimeric polypeptide disclosed herein (e.g., a chimeric switch receptor), CAR (e.g., DLL3 CAR), and CCR, a second polynucleotide or vector encoding a chimeric polypeptide (e.g., a chimeric switch receptor), CAR (e.g., DLL3 CAR), and CCR that is not encoded by the first polynucleotide or vector. In some embodiments, a polynucleotide or vector encodes a chimeric polypeptide disclosed herein (e.g., a chimeric switch receptor), a CAR (e.g., a DLL3 CAR), and a CCR. In some embodiments, the engineered immune cells comprise one or more polynucleotides encoding a DLL3 CAR and a CCR with or without a signal peptide, the DLL3 CAR comprising an amino acid sequence of SEQ ID NO: 73 or 165, and the CCR comprising an amino acid sequence of SEQ ID NO: 162. In some embodiments, the polynucleotide encodes a CCR and a DLL3 CAR with or without a signal peptide, comprising an amino acid sequence of SEQ ID NO: 74. In some embodiments, the DLL3 CAR and / or CCR further comprises a CD8 signal sequence comprising an amino acid sequence of SEQ ID NO: 1.In some embodiments, the first polynucleotide or vector encodes a chimeric switch receptor as disclosed herein, and the second polynucleotide or vector encodes both a CAR (e.g., a DLL3 CAR) and a CCR and further optionally encodes a self-cleaving peptide (e.g., a 2A peptide between the CAR and the CCR). For example, in some embodiments, the second polynucleotide or vector encodes a CCR-P2A-CAR polypeptide, e.g., a CCR-P2A-DLL3 CAR polypeptide comprising components CD8 signal sequence, TpoR (thrombopoietin receptor) (S505NW515K), IL2Rb-YY, P2A, CD8 signal sequence, rituximab mimetic epitope, 2G1 scFv, rituximab mimetic epitope, CD8α hinge, CD8α transmembrane, CD8α cytoplasmic domain (truncated), 4-1BB (TNFRSF9, CD137) cytoplasmic domain, and CD3ζ cytoplasmic domain, e.g., a CCR-P2A-DLL3 CAR polypeptide comprising the amino acid sequence of SEQ ID NO: 74, encoded by a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 117, or a polypeptide, e.g., a DLL3 CAR-P2A-CCR polypeptide comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 74.
[0052] In another aspect, the present disclosure provides an engineered immune cell comprising one or more polynucleotides encoding a DLL3 CAR and a CCR, the DLL3 CAR comprising an amino acid sequence of SEQ ID NO: 73 or 165, and the CCR comprising an amino acid sequence of SEQ ID NO: 162. In a related aspect, the present disclosure provides an engineered immune cell comprising and / or expressing a DLL3 CAR and a CCR, the DLL3 CAR comprising an amino acid sequence of SEQ ID NO: 73 or 165, and the CCR comprising an amino acid sequence of SEQ ID NO: 162. In another related aspect, the present disclosure provides a method for preparing an engineered immune cell, wherein the engineered immune cell comprises and / or expresses a DLL3 CAR and a CCR, the DLL3 CAR comprising an amino acid sequence of SEQ ID NO: 73 or 165, and the CCR comprising an amino acid sequence of SEQ ID NO: 162. In one embodiment, the method comprises introducing a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 73 or 165 and a nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 162 into a cell (e.g., an immune cell) sequentially or simultaneously. In some embodiments, a single nucleic acid (e.g., a vector, an expression vector, a retroviral vector) comprises a nucleic acid encoding an amino acid sequence of SEQ ID NO: 73 or 165 and a nucleic acid encoding an amino acid sequence of SEQ ID NO: 162. In yet another related aspect, the present disclosure provides a method of treatment using an engineered immune cell, wherein the engineered immune cell comprises and / or expresses a DLL3 CAR and a CCR, the DLL3 CAR comprising an amino acid sequence of SEQ ID NO: 73 or 165, and the CCR comprising an amino acid sequence of SEQ ID NO: 162.
[0053] In some embodiments of the engineered immune cells disclosed herein, the engineered immune cells are T cells, tumor infiltrating lymphocytes (TILs), NK cells, cells expressing TCRs, dendritic cells, or NK-T cells. In some embodiments of the engineered immune cells disclosed herein, the cells are autologous T cells. In some embodiments of the engineered immune cells disclosed herein, the cells are allogeneic T cells.
[0054] In another aspect, the present disclosure provides a cell population comprising one or more than one engineered immune cell disclosed herein. In some embodiments, the cell population comprises at least about 1×10 4 , 1x10 5 , 1x10 6 , 1x10 7 , 1x10 8 , 1x109 or 1x10 10 In one embodiment, the engineered immune cell population comprises about 1 x 10 4 About 1x10 10 The engineered immune cells provided herein.
[0055] In another aspect, the present disclosure provides a composition comprising a cell (eg, an engineered immune cell disclosed herein). In another aspect, the present disclosure provides a composition comprising a cell population disclosed herein and a pharmaceutically acceptable carrier.
[0056] On the other hand, the present disclosure provides a method for treating a disease or condition in a patient, the method comprising administering cells, such as engineered immune cells disclosed herein, to the patient. On the other hand, the present disclosure provides a method for treating a disease or condition in a patient, the method comprising administering a cell population disclosed herein to the patient. On the other hand, the present disclosure provides a method for treating a disease or condition in a patient, the method comprising administering a composition disclosed herein to the patient. In some embodiments, the patient is a human. In some embodiments, the patient is a non-human mammal.
[0057] In some embodiments of the methods of treatment disclosed herein, the patient is a person and the disease is cancer. In some embodiments, the cancer is a hematological malignancy or a solid cancer. In some embodiments, the cancer is a hematological malignancy, which is optionally selected from acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic eosinophilic leukemia (CEL), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). In some embodiments, cancer is a solid cancer. In some embodiments, the cancer is a solid cancer, optionally selected from bile duct cancer, bladder cancer, bone and soft tissue cancer, brain tumor, breast cancer, cervical cancer, colon cancer, colorectal adenocarcinoma, colorectal cancer, desmoid tumor, embryonal carcinoma, endometrial cancer, esophageal cancer, gastric cancer, gastric adenocarcinoma, glioblastoma multiforme, gynecological tumors, head and neck squamous cell carcinoma, liver cancer, lung cancer, malignant melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, primary astrocytoma, primary thyroid cancer, prostate cancer, kidney cancer, renal cell carcinoma, rhabdomyosarcoma, skin cancer, soft tissue sarcoma, testicular germ cell tumor, urothelial carcinoma, uterine sarcoma, and uterine cancer.
[0058] On the other hand, the present disclosure provides a method for preparing an engineered immune cell disclosed herein. In some embodiments, the method includes the step of introducing one or more polynucleotides and / or vectors disclosed herein into a cell (e.g., an immune cell). In some embodiments, the cell is a T cell, a tumor infiltrating lymphocyte (TIL), a NK cell, a cell expressing a TCR, a dendritic cell, or a NK-T cell. In various embodiments, the method includes using any gene editing technology, such as TALEN, zinc finger, Cas-CLOVER and CRISPR / Cas system, and / or using any known gene knockdown method, such as using any various RNA-based technology (e.g., shRNA, antisense RNA, miRNA, siRNA; see, e.g., Lam et al., Mol. Ther. -Nucleic Acids 4:e252 (2015), doi:10.1038 / mtna.2015.23; Sridharan and Gogtay, Brit. J. Clin. Pharmacol. 82:659-72 (2016)) to reduce the functional expression of a specific gene. In some embodiments, the specific gene is, for example, PD1, TRAC, TGFbR, CD70, CD52, TIM3, LAG3, CISH, cbl-b, TIGIT or A2AR.
[0059] In some embodiments of the method for preparing the engineered immune cells disclosed herein, the engineered cells are autologous T cells. In some embodiments, the engineered cells are allogeneic T cells. In some embodiments, the method includes or further includes introducing one or more genomic modifications of one or more of endogenous CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT and TCRa genes into the genome of a cell (e.g., an immune cell). In some embodiments, one or more genomic modifications completely or partially destroy and / or prevent the functional expression of one or more of endogenous CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT and TCRa genes. In some embodiments of the method for preparing the engineered immune cells disclosed herein, a polynucleotide or vector is integrated into the immune cell genome. In some embodiments, the vector is a viral vector, such as a lentiviral vector. In some embodiments, the polynucleotide or vector is integrated into the genome by random integration. In some embodiments, the polynucleotide or vector is integrated into the genome by site-specific integration mediated by homologous recombination. In some embodiments, one or more polynucleotides and / or vectors are integrated into the CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT and / or TCRa loci. In some embodiments, the method comprises integrating a first polynucleotide or vector as disclosed herein into a first genetic locus and integrating a second polynucleotide or vector as disclosed herein into a second genetic locus.
[0060] In some embodiments of the method for preparing an engineered immune cell disclosed herein, the method includes integrating a first polynucleotide or a vector site-specifically into a first genetic locus (such as a CD70 locus, a CD52 locus, a PD1 locus, a TIM3 locus, a CISH locus, a TIGIT locus, or a cbl-b locus), and integrating a second polynucleotide or a vector site-specifically into a second genetic locus (such as a TRAC locus). In some embodiments, the first polynucleotide or the vector encodes a polypeptide comprising an extracellular domain, a transmembrane domain, and one or more intracellular domains as disclosed herein, wherein the extracellular domain comprises an extracellular domain of an inhibitory protein, for example, a vector encodes a chimeric switch receptor (CSR), and the second polynucleotide or the vector encodes a CAR as described herein, for example, a DLL3 CAR as described herein, and optionally a second polynucleotide or the vector further encodes a chimeric cytokine receptor (CCR) as described herein, for example, an inducible CCR or a constitutively active CCR (CACCR). In some embodiments, CAR, CSR, and / or CCR further comprise a signal peptide. In some embodiments, the first polynucleotide or vector encodes a chimeric polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 75-115. In some embodiments, the first polynucleotide or vector encodes a chimeric polypeptide comprising an amino acid sequence at least 90% identical to any one of SEQ ID NOs: 75-115.
[0061] In various embodiments, the method for preparing the engineered immune cell provided herein can be applied to cells from any various sources. The engineered immune cell can be prepared from or derived from cells, such as stem cells or immune cells from people other than the people who will use the engineered immune cell, such as donors other than recipients (e.g., healthy volunteers), or can be prepared from or derived from cells, such as stem cells or immune cells from people (recipients) who will use the engineered immune cell, or can be derived from one or more induced pluripotent stem cells (iPSC). In various embodiments, immune cells are immune cells obtained from healthy volunteers, obtained from patients or derived from iPSC.
[0062] In another aspect, the present disclosure provides an engineered immune cell prepared by any of the methods for preparing engineered immune cells disclosed herein. In another aspect, the present disclosure provides a method of treating a condition (e.g., a cancer as described herein), the method comprising, for example, administering to a patient in need of such treatment an engineered immune cell prepared by any of the methods disclosed herein or a method comprising one or more engineered immune cells prepared by any of the methods disclosed herein (e.g., about 10 5 , 106 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 A cell population of an engineered immune cell). BRIEF DESCRIPTION OF THE DRAWINGS
[0063] Figure 1A-1B . Design of exemplary chimeric switch receptors. Figure 1A and Figure 1B Representative PD1 chimeric switch receptors are shown ( Figure 1A ) and TGFbR2 chimeric switch receptor ( Figure 1B ) schematic diagram of the domain structure. ECD: extracellular domain; TM: transmembrane domain; ICD: intracellular domain.
[0064] Figure 2A-2B In vivo data from the SHP-77 subcutaneous model are shown for the anti-tumor response and persistence of CAR T cells expressing DLL3 CAR T clone 2G1 with CCR version 15.1 or CCR version 15.3. Figure 2C-2E Anti-tumor response and persistence data as well as cytokine secretion data from the NCI-H82 subcutaneous model are shown. Figure 2F . Experimental data show that wild-type (WT) PD1 or high-affinity (HA) PD1 chimeric switch receptor (which contains CD28, CD2 or CD2 short intracellular domain) is expressed alone (upper row) or together with DLL3CAR and CCR (lower row) on the surface of primary T cells. Figure 2G .Bar graphs summarize the percentage of T cells in which CAR expression was detected (CAR+) or not detected (CAR-) and in which PD1 chimeric switch receptor expression was detected (iPD1+) or not detected (iPD1-) in cells transduced with one or both vectors (for methods, see Example 2). Figure 2H . Experimental data show the expansion of transduced T cells.
[0065] Figure 3A-3B . Cytotoxic activity of T cells expressing CAR and CCR (2G1.15.1 clone encodes both CAR and CCR) without or with a chimeric switch receptor comprising a wild-type (WT) or high-affinity (HA) PD1 domain fused to CD28, CD2, or CD2 short (also referred to herein as "truncated") intracellular domain. A series of killing assays were used to determine the cytotoxicity of T cells generated according to the method in Example 3. Compared with WT ( Figure 3A ) or HA PD1( Figure 3B) Extracellular domain-paired CD28 or CD2 short ICD enhances the cytotoxic activity of 2G1.15.1. Target cells are DMS273 (PDL1 low) (upper row) or DMS273-PDL1 (PDL1 high) (lower row). Figure 3B Exemplary sequences tested are: WT PD1-CD28, SEQ ID NO: 75; HA PD1-CD28, SEQ ID NO: 84; WT PD1-CD2, SEQ ID NO: 78; HA PD1-CD2, SEQ ID NO: 87; WT PD1-CD2 short, SEQ ID NO: 79; and HA PD1-CD2 short, SEQ ID NO: 88. For these constructs, the CD8a signal peptide (SEQ ID NO: 1) was used.
[0066] Figure 4A-4B .Cytokine secretion (IL-2 or IFNγ as an example) by various CAR T cells in the presence of target cells expressing low or high levels of PDL1. NTD: not transduced.
[0067] Figures 5A-5D T cells expressing DLL3 CAR and CCR (2G1.15.1) alone or together with one of various PD1 chimeric switch receptors or a dominant negative PD-1 construct (dnWT-PD1) were generated from one human T cell donor using multiple site-specific integration (SSI). Figure 5A Results show TALEN-mediated gene knockout efficiency at the TRAC and CD52 loci and AAV-mediated transduction efficiency of CAR and various PD1 constructs at day 6 of generation. Figure 5B . Flow cytometry graphs depict the percentage of T cells not expressing the transduced peptide, DLL3 CAR, and CCR (2G1.15.1) with or without dnWT-PD1, PD1 chimeric switch receptor at day 16 of generation. Figure 5C .Bar graphs show the mean fluorescence intensity of DLL3 CAR (left panel) and PD1 chimeric switch receptor (right panel). Figure 5D . Expansion of T cells expressing DLL3CAR and CCR (2G1.15.1) alone or together with one of the various PD1 constructs during generation. NTD: non-transduced; dnWT-PD1: dominant negative wild-type PD1.
[0068] Figures 6A-6C .Use SSI from Figures 5A-5CThe donors shown in the different human T cell donors generated T cells expressing DLL3 CAR and CCR (2G1.15.1) alone or with dominant negative HA PD1 or one of the various HA PD1 chimeric switch receptors. The named constructs and their corresponding amino acid and nucleic acid sequences are listed in Tables 3 and 4. Fig. 6A Flow cytometry results show TALEN-mediated gene knockout efficiency and AAV-mediated transduction efficiency at day 14 to generate cells expressing the indicated peptides. More than 75% of T cells lost TCRa / b expression, and most TCRa / b-negative T cells expressed DLL3 CAR and CCR. Figure 6B .The majority of T cells lost CD52 expression, and a subset of CD52-negative T cells expressed the PD1 chimeric switch receptor (bottom panel). Figure 6C . Flow cytometry graphs depict the percentage of T cells expressing DLL3 CAR and / or chimeric switch receptor at day 14 of generation. Fig.6D . T cell expansion during the generation of T cells expressing the indicated polypeptides (and see Tables 3 and 4 for the corresponding sequences). HA: high affinity; dnHACiPD1: dominant negative high affinity PD1 (Maute RL et al. Proc Natl Acad Sci USA. 2015).
[0069] Figure 7 .CD2 or CD2-short enhanced the cytotoxic activity of CAR T cells generated by SSI, similar to those generated by lentiviral transduction. T cells co-expressing DLL3 CAR and CCR (2G1.15.1) alone or with one of the various PD1 chimeric switch receptors (with either the wild-type (WT) PD1 extracellular domain or the high-affinity (HA) PD1 extracellular domain) were cytotoxic against target cells expressing low or high levels of DLL3 and PDL1. Dominant negative PD1 (dnWT PD1) alone did not enhance cytotoxic activity in the assay, whereas switch receptors with intracellular signaling domains from CD2 or CD2-short enhanced the cytotoxic activity of DLL3 CAR.
[0070] Figures 8A-8B . Fig. 8A Data show serial killing assays of CAR T cells expressing an additional PD1 chimeric switch receptor compared to parental CAR T cells all generated by site-specific integration. Figure 8B Results from the single-stimulation long-term killing assay showed enhanced cytotoxicity when co-cultured with NCI-H82-PDL1 cells and simultaneous expansion of CAR-T cells co-expressing different PD1 chimeric switch receptors.
[0071] Figures 9A-9BData are presented showing cytokine secretion from T cells expressing chimeric switch receptors generated by site-specific integration.
[0072] Figures 10A-10C Data are presented showing cytokine secretion from CAR T cells expressing chimeric switch receptors generated by site-specific integration. When CAR T cells were co-cultured with PDL1 high cells (condition D), many chimeric switch receptors induced higher levels of cytokine secretion than when CAR T cells were co-cultured with PDL1 low DMS273 cells (condition C). Data values are in Fig. 10C Shown in.
[0073] Fig.11 Data are presented showing expansion of DLL3 CAR T (2G1.15.1) cells co-expressing one of the various PD1 chimeric switch receptors in the absence of target cells or growth factors. Total viable cell counts were quantified using flow cytometry.
[0074] Figures 12A-12B It is shown that at low expression levels ( Fig. 12A ) or high level ( Fig. 12B Results of long-term killing assays at different E:T ratios of target cells expressing DLL3 CAR, DLL3 and CAR T cells without CCR (2G1) and co-expressing a dominant negative receptor for PD1 (DN PD1) or one of various PD1 chimeric switch receptors. CAR T cells were generated by LVV transduction.
[0075] Figures 12C-12D PDL1 low target cells ( Fig. 12C ) or PDL1 high target cells ( Fig.12D ) and DLL3 CAR (2G1) T cells, where DLL3 CAR T cells were generated by multiple SSI and co-expressed one of various PD1 chimeric switch receptors (iPD-1CD2sh, iPD1-CD28.YMFM) or inducible chimeric cytokine receptors (iPD1-15.1, iPD1-15.3). Results from CAR T cells from two different donors are shown. Fig.12E Results are shown for expansion of total viable cells or CAR+DLL3 CAR T cells co-expressing one of the various PD1 chimeric switch receptors or inducible PD1 chimeric cytokine receptors in the absence of target cells or growth factors. Results are shown for CAR T cells from two different donors. Figures 12A-12EThe PD1 chimeric switch receptors tested in the assay comprised a high affinity (HA) PD1 ECD, a CD2 transmembrane domain, and a truncated CD2 signaling domain (iPD1-CD2sh), or a CD28 transmembrane domain and a variant CD28 signaling domain YMFM (iPD1-CD28 YMFM) or AYAA (iPD1-CD28 AYAA). The PD1 inducible chimeric cytokine receptors tested comprised a HA PD1 ECD, a variant TPOR transmembrane domain (TPORN+4), and an IL2Rb signaling domain containing the amino acid sequence of SEQ ID NO: 4 (iPD1-15.1) or SEQ ID NO: 180 (iPD1-15.3). DLL3 CAR (2G1) T cells generated by lentiviral transduction were used for comparison. NTD: Not transduced.
[0076] Figures 13A-13B Depicted are exemplary CD70 CAR T cells and CD70 high target cells ( Fig.13A ) or CD70 low target cells ( Fig. 13B ) (Results of long-term killing assays at different E:T ratios expressing low (top graph) or high (bottom graph) levels of PDL1). DETAILED DESCRIPTION
[0077] The present disclosure provides chimeric polypeptides (particularly chimeric switch receptors) and related polynucleotides, vectors, engineered cells (e.g., engineered immune cells), compositions, methods for preparing engineered cells (e.g., engineered immune cells), and methods of treatment. The present disclosure provides many advantages, including improvements in CAR T cell therapy.
[0078] As described in detail herein, in the chimeric switch receptors disclosed herein containing an extracellular domain (ectodomain) derived from PD1, the extracellular domain can be a wild-type sequence, or modified to bind to a PD1 ligand with higher affinity. The high-affinity PD1 extracellular domain can enable the chimeric switch receptor to more effectively (i) compete with endogenous PD1 for binding to its ligand, and (ii) transmit costimulatory signals in a PDL1 / 2 low (or TGFb low) environment.
[0079] In solid tumors that express little or no co-stimulatory ligands, coupling of inhibitory signals to co-stimulatory signals can overcome the need for cognate co-stimulation.
[0080] Chimeric switch receptors can be fused to various intracellular co-stimulatory signaling domains individually or in tandem. Tandem fusion will allow two or more co-stimulatory signaling domains to be activated simultaneously upon ligand binding.
[0081] In the case where the intracellular signaling domain does not have a transmembrane domain (e.g., MyD88), an orthogonal transmembrane domain is used to localize MyD88 to the cell membrane. For example, the PD1 transmembrane domain can be used to minimize tonic signaling of the chimeric switch receptor.
[0082] Individual intracellular co-stimulatory domains can be optimized to reduce carrier cargo and enhance functional activity by removing non-signaling interfering sequences or negative regulatory sequences (eg, CD2 short).
[0083] General Technology
[0084] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the following literature, such as Molecular Cloning: A Laboratory Manual, 2nd Edition (Sambrook et al., 1989) Cold Spring Harbor Press; Oligonucleotide Synthesis (MJ Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (JE Cellis, ed., 1998) Academic Press; Animal Cell Culture (RI Freshney, ed., 1987); Introduction to Cell and Tissue Culture (JP Thayer and PE Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (JP Cellis, ed., 1998) Academic Press; Procedures (A. Doyle, JB Griffiths and DG Newell, eds., 1993-1998) John Wiley and Sons; Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FMAusubel et al., eds., 1987); PCR: The Polymerase Chain Reaction (Mullis et al., eds., 1994); Current Protocols in Immunology (J.E. Coligan et al., eds., 1991); Short Protocols in Molecular Biology (John Wiley & Sons, 1999); Immunobiology (CA Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, eds., Oxford University Press, 1994); Press, 2000); Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press), 1999); The Antibodies (M. Zanetti and JD Capra, eds., Harwood Academic Publishers, 1995). For example, gene editing techniques using TALEN, CRISPR / Cas9 and megaTAL nucleases are within the skill of the art and are fully explained in the literature, such as T. Gaj et al., Genome-Editing Technologies: Principles and Applications, Cold Spring Harb Perspect Biol 2016;8:a023754 and citations therein.
[0085] definition
[0086] Unless otherwise specified, the terms "a" or "an" should be interpreted to mean "at least one or more".
[0087] As used herein, "autologous" means a cell, cell line, or population of cells obtained from a subject for use in treating the subject.
[0088] As used herein, "allogeneic" means a cell or population of cells that is not obtained from the subject but rather is obtained from a donor for treating the subject.
[0089] As used herein, the term "endogenous" refers to any material that originates or originates from within an organism, cell, tissue or system.
[0090] As used herein, the term "exogenous" refers to any material introduced or generated from outside an organism, cell, tissue, or system.
[0091] As used herein, "immune cell" refers to a cell of hematopoietic origin that is functionally involved in the initiation and / or execution of an innate and / or adaptive immune response. Examples of immune cells include T cells, such as α / βT cells and γ / δT cells, regulatory T (Treg) cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and bone marrow-derived phagocytes.
[0092] As used herein, the term "expression" refers to the transcription and / or translation of a specific nucleotide sequence driven by a promoter.
[0093] As used herein, "expression vector" refers to a vector comprising a recombinant polynucleotide comprising an expression control sequence operably linked to a nucleotide sequence to be expressed. Expression vectors include all vectors known in the art, including cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) incorporating recombinant polynucleotides.
[0094] The engineered immune cells of the present disclosure express, for example, functionally express chimeric polypeptides, such as chimeric switch receptors as disclosed herein.For example, the engineered immune cells of the present disclosure can functionally express chimeric polypeptides from exogenous nucleic acids encoding antigen-binding proteins introduced into cells by the technology described herein, such as chimeric switch receptor proteins, and / or they can include genomic modifications, such as endogenous genes (such as CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT and / or TCR a) mutations that reduce or eliminate the functional expression of genes at genomic modification sites, and / or they can express one or more additional proteins (e.g., CAR and / or CCR) from exogenous nucleic acids introduced into cells by the technology described herein. As described herein, the engineered immune cells of the present disclosure can be derived from cells, such as immune cells obtained from various sources, such as prepared by the cells.
[0095] As used herein, "functionally expressing" a gene means that the gene is expressed, and expression produces a functional gene final product. For example, if a gene encodes a protein, then if the expression of the gene ultimately produces a functional protein, the cell functionally expresses the gene. Therefore, for example, if a gene is not transcribed, or the expression of the gene ultimately produces an untranslated RNA, or translation only produces a non-functional protein, such as a protein that is not correctly folded or is not transported to its site of action (e.g., a membrane for a membrane-bound protein), the gene is not functionally expressed. Functional expression can be measured directly (e.g., by measuring the gene product itself) or indirectly (e.g., by measuring the effect of the gene product).
[0096] As used herein, "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one nucleic acid sequence is affected by the other. For example, a promoter is operably linked to a coding sequence when the promoter is able to affect the expression of the coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter).
[0097] As used herein, "expression control sequence" means a nucleic acid sequence that directs transcription of a nucleic acid. An expression control sequence can be a promoter, such as a constitutive or inducible promoter, or an enhancer. An expression control sequence is operably linked to a nucleic acid sequence to be transcribed.
[0098] "Promoter" and "promoter sequence" are used interchangeably and refer to a DNA sequence that is capable of controlling the expression of a coding sequence or functional RNA. Typically, the coding sequence is located 3' to the promoter sequence. It will be appreciated by those skilled in the art that different promoters can direct the expression of a gene in different tissues or cell types, or at different developmental stages, or in response to different environmental or physiological conditions.
[0099] In any of the vectors disclosed herein, the vector optionally includes a promoter disclosed herein.
[0100] "Host cell" includes a single cell or cell culture that can be or has been a recipient of a vector for incorporating a polynucleotide insert. Host cells include the progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. Host cells include cells transfected in vivo with a polynucleotide of the present disclosure.
[0101] As used herein, the term "extracellular ligand binding domain" refers to an oligopeptide or polypeptide capable of binding a ligand. Preferably, the domain will be capable of interacting with a cell surface molecule. For example, an extracellular ligand binding domain can be selected to recognize a ligand that acts as a cell surface marker on a target cell associated with a specific disease state. The term "stem domain" is used herein to refer to any oligopeptide or polypeptide that acts to connect a transmembrane domain to an extracellular ligand binding domain. Specifically, the stem domain is used to provide greater flexibility and accessibility to the extracellular ligand binding domain.
[0102] The term "intracellular signaling domain" refers to the portion of a protein that transduces effector signaling functions and directs the cell to perform a specialized function.
[0103] As used herein, "costimulatory molecules" refer to cognate binding partners that specifically bind to costimulatory ligands on T cells, thereby mediating the costimulatory response of cells, such as but not limited to proliferation. Costimulatory molecules include but are not limited to MHC class I molecules, BTLA and Toll ligand receptors. Examples of costimulatory molecules include CD27, CD28, CD8, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3 and ligands specifically bound to CD83, etc.
[0104] "Co-stimulatory ligand" refers to a molecule on an antigen presenting cell that specifically binds to a cognate co-stimulatory signal molecule on a T cell, thereby providing a signal in addition to the primary signal provided by, for example, the binding of the TCR / CD3 complex to a peptide-loaded MHC molecule, which mediates T cell responses, including but not limited to proliferation activation, differentiation, etc. Costimulatory ligands may include, but are not limited to, CD7, B7-1 (CD80), B7-2 (CD86), PD-L2, 4-1BBL, OX40L, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecules (ICAM, CD30L, CD40, CD70, CD83, HLA-G, MICA, M1 CB, HVEM, lymphotoxin beta receptor, 3 / TR6, ILT3, ILT4, agonists or antibodies that bind to Toll ligand receptors, and ligands that specifically bind to B7-H3. Costimulatory ligands also particularly encompass antibodies that specifically bind to costimulatory molecules present on T cells, such as, but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, ICOS, lymphocyte function-associated antigen 1 (LFA-1), CD2, CD7, LTGHT, NKG2C, B7-H3, and ligands that specifically bind to CD83.
[0105] "Antibody" is an immunoglobulin molecule that can specifically bind to a target (such as carbohydrates, polynucleotides, lipids, polypeptides, etc.) through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. As used herein, the term not only covers complete (or full-length) polyclonal antibodies or monoclonal antibodies, but also covers its antigen-binding fragments (such as Fab, Fab', F(ab')2 and Fv), and any other modified configurations of immunoglobulin molecules comprising antigen recognition sites, including, for example, but not limited to single-chain (scFv) and domain antibodies (including, for example, shark and camel antibodies) and fusion proteins comprising antibodies. Antibodies include antibodies of any class, such as IgG, IgA or IgM (or its subclass), and antibodies do not need to have any specific class. Immunoglobulins can be assigned to different classes according to the antibody amino acid sequence of the constant region of their heavy chains. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The heavy chain constant regions corresponding to the different classes of immunoglobulins are called α, δ, ε, γ and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known.
[0106] As used herein, the term "antigen-binding fragment" or "antigen-binding portion" of an antibody refers to one or more fragments of an intact antibody that retain the ability to specifically bind to a given antigen. The antigen-binding function of an antibody can be performed by a fragment of an intact antibody. Examples of binding fragments encompassed in the term "antigen-binding fragment" of an antibody include Fab; Fab'; F(ab')2; Fd fragments consisting of VH and CH1 domains; Fv fragments consisting of the VL and VH domains of a single arm of an antibody; single domain antibody (dAb) fragments (see, e.g., Ward et al., Nature 341:544-546, 1989) and individual complementary determining regions (CDRs).
[0107] The term "specific binding" to a target is used to refer to an antibody, antibody conjugate or polypeptide, and methods for determining such specific binding are also well known in the art. A molecule is said to exhibit "specific binding" if it reacts or associates with a particular cell or substance more frequently, more rapidly, for a longer duration and / or with greater affinity than an alternative cell or substance. An antibody "specifically binds" to a target if it binds to it with greater affinity, avidity, more easily and / or with a longer duration than it binds to other substances. It should also be understood by reading this definition that, for example, an antibody (or part or epitope) that specifically binds to a first target may or may not specifically bind to a second target. Therefore, "specific binding" does not necessarily require (although it may include) exclusive binding.
[0108] The "variable region" of an antibody refers to the variable region of an antibody light chain or the variable region of an antibody heavy chain, alone or in combination. As known in the art, the variable regions of the heavy and light chains are each composed of four framework regions (FRs) connected by three complementary determining regions (CDRs) (also referred to as hypervariable regions). The CDRs in each chain are tightly bound together by the FRs and, together with the CDRs in the other chain, contribute to the formation of the antigen binding site of the antibody. There are several techniques for determining CDRs, such as methods based on cross-species sequence variability (i.e., Kabat et al., Sequences of Proteins of Immunological Interest, (5th ed., 1991, National Institutes of Health, Bethesda, MD); an approach based on crystallographic studies of antigen-antibody complexes (Al-lazikani et al., 1997, J. Molec. Biol. 273:927-948), the Chothia system (i.e., Chothia and Lesk, J. Mol. Biol. (1987) 196(4):901-917). As used herein, CDRs may refer to CDRs defined by either approach or by a combination of both approaches.
[0109] The "CDR" of a variable domain is an amino acid residue within the variable region that is identified according to the definitions of Kabat, Chothia, accumulation of both Kabat and Chothia, AbM, contact and / or conformational definitions, or any CDR determination method well known in the art. Antibody CDRs can be identified as hypervariable regions originally defined by Kabat et al. See, e.g., Kabat et al., 1992, Protein Sequences of Immunological Significance, 5th Edition, Public Health Service, NIH, Washington DC. The position of the CDR can also be identified as the structural loop structure originally described by Chothia et al. See, e.g., Chothia et al., Nature 342:877-883, 1989. Other methods of CDR identification include the "AbM definition," which is a compromise between Kabat and Chothia and is derived using the AbM antibody modeling software (now Oxford Molecular) from Oxford Molecular. ) derived, or based on the "contact definition" of CDRs based on observed antigen contacts, which is described in MacCallum et al., Journal of Molecular Biology, 262: 732-745, 1996. In another method referred to herein as the "conformational definition" of CDRs, the positions of CDRs can be identified as residues that make an enthalpic contribution to antigen binding. See, for example, Makabe et al., Journal of Biological Chemistry, 283: 1156-1166, 2008. Other CDR boundary definitions may still not strictly follow one of the above methods, but will nevertheless overlap with at least a portion of the Kabat CDRs, but in view of the prediction or experimental discovery that a particular residue or residue group or even the entire CDR does not significantly affect antigen binding, the boundary definition may be shortened or lengthened. As used herein, CDRs may refer to CDRs defined by any method known in the art, including a combination of methods. The methods used herein can utilize CDRs defined according to any of these methods. For any given embodiment containing more than one CDR, the CDRs may be defined according to any of the Kabat, Chothia, extension, AbM, contact, AHo, and / or conformational definitions.
[0110] The antibodies disclosed herein can be produced using techniques well known in the art, such as recombinant techniques, phage display techniques, synthetic techniques, or a combination of such techniques or other techniques well known in the art (see, e.g., Jayasena, SD, Clin. Chem., 45: 1628-50, 1999 and Fellouse, FA et al., J. Molecular Biology, 373(4): 924-40, 2007).
[0111] As known in the art, "polynucleotide" or "nucleic acid" as used interchangeably herein refers to a nucleotide chain of any length, and includes DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogs or any substrate that can be incorporated into the chain by DNA or RNA polymerase. The polynucleotides can include modified nucleotides, such as methylated nucleotides and their analogs. If present, modifications to the nucleotide structure can be imparted before or after assembling the chain. The sequence of nucleotides can be interrupted by non-nucleotide components. The polynucleotides can be further modified after polymerization, such as by combining with a labeling component. Other types of modifications include, for example, "capping", substitution of one or more of the naturally occurring nucleotides with an analog; internucleotide modifications such as those with uncharged bonds (e.g., methylphosphonates, phosphotriesters, phosphoramides, carbamates, etc.) and those with charged bonds (e.g., phosphorothioates, phosphorodithioates, etc.), those containing side groups such as proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidized metals, etc.), those containing alkylating agents, those with modified bonds (e.g., alpha anomeric nucleic acids, etc.), and unmodified forms of polynucleotides. In addition, any hydroxyl group usually present in sugar can be replaced by phosphonate group, phosphate group, protected by standard protecting groups or activated to prepare other bonds relative to other nucleotides, or can be conjugated to a solid support. 5' and 3' terminal OH can be partially phosphorylated or replaced with amine or organic end-capping groups with 1 to 20 carbon atoms. Other hydroxyls can also be derived into standard protecting groups. Polynucleotides can also contain similar forms of ribose or deoxyribose commonly known in the art, including for example 2'-O-methyl-, 2'-O-allyl, 2'-fluoro- or 2'-azido-ribose, carbocyclic sugar analogs, α-anomeric sugars or β-anomeric sugars, epimeric sugars (such as arabinose, xylose or lyxose), pyranose, furanose, sedoheptulose, acyclic analogs and abasic nucleoside analogs (such as methyl riboside). One or more phosphodiester bonds can be replaced by alternative linking groups. These replaceable linking groups include, but are not limited to, embodiments in which the phosphate is replaced by P(O)S ("thioate"), P(S)S ("disulfide"), (O)NR2 ("amidate"), P(O)R, P(O)OR', CO or CH2 ("formalate"), wherein each R or R' is independently H or a substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (-O-) linkage, an aryl, an alkenyl, a cycloalkyl, a cycloalkenyl or an aralkyl group.Not all bonds in a polynucleotide need to be identical.The above description applies to all polynucleotides mentioned herein, including RNA and DNA.
[0112] As used herein, "transfection" refers to the uptake of exogenous or heterologous RNA or DNA by a cell. When exogenous or heterologous RNA or DNA has been introduced into a cell, the cell has been "transfected" by such RNA or DNA. When the transfected RNA or DNA affects a phenotypic change, the cell has been "transformed" by the exogenous or heterologous RNA or DNA. The transforming RNA or DNA can be integrated (covalently linked) into the chromosomal DNA that makes up the genome of the cell.
[0113] As used herein, "transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragment are referred to as "transgenic" or "recombinant" or "transformed" organisms.
[0114] As used herein, "substantially pure" refers to a material that is at least 50% pure (i.e., free of contaminants), more preferably at least 90% pure, more preferably at least 95% pure, yet more preferably at least 98% pure, and most preferably at least 99% pure. The term "competition" as used herein with respect to antibodies means that the first antibody or its antigen-binding fragment (or portion) binds to the epitope in a manner very similar to the binding of the second antibody or its antigen-binding portion, such that the binding result of the first antibody to its cognate epitope in the presence of the second antibody is detectably reduced compared to the binding of the first antibody in the absence of the second antibody. An alternative, in which the binding of the second antibody to its epitope is also detectably reduced in the presence of the first antibody, may be, but is not necessarily, the case. That is, the first antibody may inhibit the binding of the second antibody to its epitope, while the second antibody does not inhibit the binding of the first antibody to its corresponding epitope. However, in the case where each antibody detectably inhibits the binding of the other antibody to its cognate epitope or ligand, whether to the same, greater or lesser extent, the antibodies are considered to "cross-compete" with each other to bind to their corresponding epitopes. The present disclosure encompasses competing antibodies and cross-competing antibodies. Regardless of the mechanism by which such competition or cross-competition occurs (e.g., steric hindrance, conformational changes, or binding to a common epitope or portion thereof), the skilled artisan will understand, based on the teachings provided herein, that such competing and / or cross-competing antibodies are contemplated and can be used in the methods disclosed herein.
[0115] As used herein, "treatment" is a method for obtaining a beneficial or desired clinical outcome. For the purposes of this disclosure, a beneficial or desired clinical outcome includes, but is not limited to, one or more of the following: reducing (or destroying) the proliferation of tumors or cancer cells, inhibiting the metastasis of tumor cells, shrinking or reducing the size of a tumor, alleviating a disease (e.g., cancer), alleviating symptoms caused by a disease (e.g., cancer), improving the quality of life of a person suffering from a disease (e.g., cancer), reducing the dose of other drugs required to treat a disease (e.g., cancer), delaying the progression of a disease (e.g., cancer), curing a disease (e.g., cancer) and / or prolonging the survival of a subject suffering from a disease (e.g., cancer).
[0116] "Improvement" refers to the alleviation or improvement of one or more symptoms compared to no treatment. "Improvement" also includes shortening or reducing the duration of symptoms. As used herein, the "effective dose" or "effective amount" of a drug, compound or pharmaceutical composition is an amount sufficient to achieve any one or more beneficial or desired results. For preventive purposes, the beneficial or desired results include eliminating or reducing the risk of a disease (including biochemical, histological and / or behavioral symptoms of the disease, complications of the disease and intermediate pathological phenotypes that occur during the development of the disease), reducing its severity or delaying its onset. For therapeutic purposes, the beneficial or desired results include clinical results, such as a reduction or improvement in the incidence of one or more symptoms of various diseases or conditions (such as cancer), reducing the dose of other drugs required for the treatment of the disease, enhancing the effect of another drug and / or delaying the progression of the disease. The effective dose can be administered once or multiple times. For the purposes of this disclosure, an effective dose of a drug, compound or pharmaceutical composition is an amount sufficient to directly or indirectly complete a preventive or therapeutic treatment. As understood in a clinical context, an effective dose of a drug, compound or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound or pharmaceutical composition. Thus, an "effective dose" may be considered in the context of administration of one or more therapeutic agents, and an individual agent may be considered to be given in an effective amount if the desired result can be achieved or accomplished in combination with one or more other agents.
[0117] As used herein, a "subject" is any mammal, such as a human or a monkey. Mammals include, but are not limited to, farm animals, sports animals, pets, primates, horses, dogs, cats, mice, and rats. In an exemplary embodiment, the subject is a human. In an exemplary embodiment, the subject is a monkey, such as a cynomolgus monkey.
[0118] As used herein, "vector" means a construct capable of delivering and preferably expressing one or more genes or sequences of interest in a host cell. Examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmids, cosmids or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as production cells.
[0119] As used herein, "pharmaceutically acceptable carriers" or "pharmaceutically acceptable excipients" include any material that allows the active ingredient to retain biological activity when combined with the ingredient and is non-reactive with the subject's immune system. Examples include, but are not limited to, any standard pharmaceutical carrier, such as phosphate buffered saline, water, emulsions such as oil / water emulsions, and various types of wetting agents. Preferred diluents for aerosol or parenteral administration are phosphate buffered saline (PBS) or physiological (0.9%) saline. Compositions of the present disclosure including such carriers are formulated by well-known conventional methods (see, e.g., Remington's Pharmaceutical Sciences, 18th ed., A. Gennaro, ed., Mack Publishing Co., Easton, PA, 1990; and Remington, The Science and Practice of Pharmacy, 21st ed. Mack Publishing Co., 2005).
[0120] As used herein, "allogeneic reactivity" refers to the ability of T cells to recognize MHC complexes not encountered during thymic development. Alloreactivity manifests clinically as host versus graft rejection and graft versus host disease.
[0121] References herein to "about" a value or parameter include (and describe) embodiments directed to the value or parameter itself plus or minus 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%. For example, descriptions referring to "about X" include descriptions of "X". Numerical ranges include the numbers defining the range.
[0122] It should be understood that when an embodiment is described with the language "comprising" anywhere herein, otherwise similar embodiments described according to "consisting of" and / or "consisting essentially of" are also provided.
[0123] Where aspects or embodiments of the present disclosure are described according to Markush groups or other alternative groupings, the present disclosure encompasses not only the entire group listed as a whole, but also each member of the group individually and all possible subgroups of the main group, as well as the main group lacking one or more of the group members. The present disclosure also contemplates explicitly excluding one or more of any group members in the disclosed and / or claimed embodiments.
[0124] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. In the event of a conflict, the present specification (including definitions) shall prevail. Throughout this specification and claims, the word "comprise" or variations such as "comprises" or "comprising" shall be understood to imply the inclusion of the stated integer or groups of integers, but not the exclusion of any other integer or groups of integers. Unless the context requires otherwise, singular terms shall include pluralities and plural terms shall include the singular.
[0125] Exemplary methods and materials are described herein, but methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure. The materials, methods, and examples are illustrative only and are not intended to be limiting.
[0126] An "antigen binding protein" includes one or more antigen binding domains. As used herein, "antigen binding domain" means any polypeptide that binds to a specified target antigen. In some embodiments, the antigen binding domain binds to an antigen on a tumor cell. In some embodiments, the antigen binding domain binds to an antigen on a cell involved in a hyperproliferative disease or involved in a viral or bacterial antigen.
[0127] Antigen binding domains include, but are not limited to, antibody binding regions that are immunologically functional fragments. The term "immunologically functional fragment" (or "fragment") of an antigen binding domain is a species of an antigen binding domain that includes a portion of an antibody that lacks at least some of the amino acids present in the full-length chain but is still capable of specifically binding to a target antigen (however the portion is obtained or synthesized). Such fragments have biological activity because the fragments bind to the target antigen and can compete with other antigen binding domains comprising intact antibodies for binding to a given epitope.
[0128] Immunologically functional immunoglobulin fragments include, but are not limited to, scFv fragments, Fab fragments (Fab', F(ab')2, etc.), one or more complementarity determining regions ("CDRs"), diabodies (heavy chain variable domains and light chain variable domains are located on the same polypeptide, connected by a short peptide linker that is too short to allow pairing between the two domains on the same chain), domain antibodies, bivalent antigen binding domains (comprising two antigen binding sites), multispecific antigen binding domains, and single-chain antibodies. These fragments may be derived from any mammalian source, including, but not limited to, humans, mice, rats, camels, or rabbits. As will be appreciated by those skilled in the art, antigen binding domains may include non-protein components.
[0129] The variable region usually exhibits the same general structure of a relatively conservative framework region (FR) joined by three hypervariable regions (CDRs). The CDRs from the two chains of each pair are usually aligned by a framework region that can bind to a specific epitope. From the N-terminus to the C-terminus, both the light chain variable region and the heavy chain variable region usually include domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. By convention, the CDR regions in the heavy chain are usually referred to as HC CDR1, CDR2, and CDR3. The CDR regions in the light chain are usually referred to as LC CDR1, CDR2, and CDR3.
[0130] In some embodiments, the antigen binding domain includes one or more complementary binding regions (CDRs) present in the full-length light or heavy chains of an antibody, and in some embodiments includes a single heavy and / or light chain or a portion thereof. These fragments can be produced by recombinant DNA technology or can be produced by enzyme or chemical cleavage of the antigen binding domain (comprising a complete antibody).
[0131] In some embodiments, the antigen binding domain is an antibody or a fragment thereof, comprising one or more of its complementary determining regions (CDRs). In some embodiments, the antigen binding domain is a single chain variable fragment (scFv), comprising light chain CDRs: CDR1, CDR2, and CDR3, and heavy chain CDRs: CDR1, CDR2, and CDR3.
[0132] The assignment of amino acids to each of the framework, CDRs and variable domains is generally made according to the following numbering schemes: Kabat numbering (see, e.g., Kabat et al., Sequences of Proteins of Immunological Significance, 5th ed., NIH Publication No. 91-3242, Bethesda, MD 1991), Chothia numbering (see, e.g., Chothia and Lesk, (1987), J. Mol. Biol. 196:901-917; Al-Lazikani et al., (1997) J. Mol. Biol. 273:927-948; Chothia et al., (1992) J. Mol. Biol. 227:799-817; Tramontano et al., (1990) J. Mol. Biol. 215(1):175-82; and U.S. Pat. No. 7,709,226), contact numbering, AbM scheme (Antibody Modeling Program, Oxford Molecular Biology, Inc. Molecular)) or AHo system (Honneger and Pluckthun, Journal of Molecular Biology (2001) 309(3):657-70).
[0133] In some embodiments, the antigen binding domain is a recombinant antigen receptor. As used herein, the term "recombinant antigen receptor" refers to a non-naturally occurring surface receptor, which includes an extracellular antigen binding domain or an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. In some embodiments, the recombinant antigen receptor is a chimeric antigen receptor (CAR). Chimeric antigen receptor (CAR) is well known in the art. CAR is a fusion protein including an antigen recognition portion, a transmembrane domain, and a T cell activation domain (see, e.g., Eshhar et al., Proceedings of the National Academy of Sciences of the United States of America, 90 (2): 720-724 (1993)).
[0134] In some embodiments, the intracellular domain of the recombinant antigen receptor includes a co-stimulatory domain and an ITAM-containing domain. In some embodiments, the intracellular domain of the recombinant antigen receptor includes an intracellular protein or a functional variant thereof (e.g., truncated, inserted, deleted or substituted).
[0135] As used herein, the term "extracellular ligand binding domain" or "extracellular antigen binding domain" refers to a polypeptide that can bind to a ligand or antigen or can interact with a cell surface molecule, such as a ligand or surface antigen. For example, an extracellular ligand binding domain or antigen binding domain can be selected to recognize a ligand that acts as a cell surface marker on a target cell associated with a specific disease state (e.g., a tumor-specific antigen). In some embodiments, the antigen binding domain includes an antigen binding fragment or antigen binding portion of an antibody or an antibody. In some embodiments, the antigen binding domain includes Fv or scFv, Fab or scFab, F(ab')2 or scF(ab')2, Fd, a monomer, an affibody, a camel antibody, a VHH antibody, a single domain antibody or a darpin. In some embodiments, the ligand binding domain includes a partner of a binding pair, such as a ligand that binds to a surface receptor, or an extracellular domain of a surface receptor that binds to a ligand.
[0136] The term "stem domain" or "hinge domain" is used interchangeably herein to refer to any polypeptide that functions to connect a transmembrane domain to an extracellular ligand-binding domain. In particular, the stem domain is often used to provide greater flexibility and accessibility to the extracellular ligand-binding domain.
[0137] The term "intracellular signaling domain" refers to the portion of a protein that transduces effector signaling functions and directs the cell to perform a specialized function.
[0138] Carrier
[0139] Expression vectors and methods for administering polynucleotide compositions are known in the art and are further described herein.
[0140] In another aspect, the present disclosure provides a method of making any of the polynucleotides described herein.
[0141] The present disclosure also encompasses polynucleotides complementary to any such sequence. The polynucleotide can be single-stranded (coding or antisense) or double-stranded, and can be a DNA (genomic, cDNA or synthetic) or RNA molecule. The RNA molecule comprises an HnRNA molecule containing introns and corresponding to a DNA molecule in a one-to-one manner, and an mRNA molecule that does not contain introns. Additional coding or non-coding sequences may but need not be present in the polynucleotide of the present disclosure, and the polynucleotide may but need not be connected to other molecules and / or carrier materials.
[0142] Polynucleotides may include native sequences (i.e., endogenous sequences encoding antibodies or portions thereof), or may include variants of such sequences. Polynucleotide variants contain one or more substitutions, additions, deletions and / or insertions, such that the immunoreactivity of the encoded polypeptide is not diminished relative to the natural immunoreactive molecule. The effect of the immunoreactivity of the encoded polypeptide may generally be assessed as described herein. Variants preferably exhibit at least about 70% identity to the polynucleotide sequence encoding the natural antibody or portion thereof, more preferably at least about 80% identity, more preferably at least about 90% identity, and most preferably at least about 95% identity. If the sequences of nucleotides or amino acids in the two sequences are identical when the maximum correspondence is aligned as described below, the two polynucleotide or polypeptide sequences are referred to as "identical". Comparison between two sequences is generally performed by comparing sequences on a comparison window to identify and compare local regions of sequence similarity. As used herein, a "comparison window" refers to a segment of at least about 20, typically about 30 to about 75 or about 40 to about 50 contiguous positions in which a sequence can be compared to a reference sequence having the same number of contiguous positions after the two sequences are optimally aligned.
[0143] Sequences can be optimally aligned for comparison using the Megalign program in the Lasergene bioinformatics software suite (DNASTAR, Madison, WI) using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, MO, 1978, "A model of evolutionary change in proteins - a matrix for detecting long-range relationships," in Dayhoff, MO (ed.), Protein Sequence and Structure Atlas, Volume 5, Supplement 3, pp. 345-358, National Biomedical Research Foundation, Washington, DC; Hein J., 1990, Unified Approach to Alignment and Phylogenes, pp. 626-645, Methods in Enzymology, Volume 183, Academic Press, Inc., San Diego, CA; Higgins, DG and Sharp, PM, 1989, Computer Applications in the Biological Sciences (CABIOS), 5: 151-153; Myers, EW and Muller, J., 1990, Unified Approach to Alignment and Phylogenes, pp. 626-645, Methods in Enzymology, Volume 183, Academic Press, Inc., San Diego, CA; Higgins, DG and Sharp, PM, 1989, Computer Applications in the Biological Sciences (CABIOS), 5: 151-153; W., 1988, "Computer Applications in Biological Sciences", 4:11-17; Robinson, ED, 1971, "Combine Theory", 11:105; Santou, N., Nes, M., 1987, "Mol. Biol. Evolution", 4:406-425; Sneath, PHA and Sokal, RR, 1973, "Numerical Classification - Principles and Practice of Numerical Classification", Freeman Press, St. Francis, California; Wilbur, WJ and Lipman, DJ, 1983, "Proceedings of the National Academy of Sciences of the United States of America", 80:726-730.
[0144] In some embodiments, the "percentage of sequence identity" is determined by comparing two optimally aligned sequences over a comparison window of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may include additions or deletions (i.e., gaps) of 20 percent or less, typically 5 to 15 percent or 10 to 12 percent, compared to a reference sequence (the reference sequence does not include additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions where the same nucleic acid base or amino acid residue appears in the two sequences to derive the number of matched positions; dividing the number of matched positions by the total number of positions in the reference sequence (i.e., window size); and multiplying the result by 100 to derive the percentage of sequence identity.
[0145] The present disclosure provides variant polynucleotides or variant polypeptides compared to reference polynucleotides or reference polypeptides, respectively. Variants can be produced by one or more insertions, one or more deletions, and / or one or more substitutions. In some embodiments, the variant polypeptide can contain one or more amino acid insertions, one or more amino acid deletions, and / or one or more amino acid substitutions compared to the reference polypeptide. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. Exemplary conservative amino acid residues are as follows:
[0146] Table A: Amino Acid Substitutions
[0147]
[0148] Variants may also or alternatively be substantially homologous to a native gene or a portion or complement thereof. Such polynucleotide variants are capable of hybridizing under moderately stringent conditions with a naturally occurring DNA sequence encoding a native antibody (or a complementary sequence).
[0149] Suitable "moderately stringent conditions" include pre-washing in a solution of 5×SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridization overnight at 50°C-65°C, 5×SSC; followed by washing twice with each of 2×, 0.5× and 0.2×SSC containing 0.1% SDS at 65°C for 20 minutes.
[0150] As used herein, "high stringency conditions" or "high stringency conditions" refer to those that: (1) employ low ionic strength and high temperature for washing, for example, 0.015 M sodium chloride / 0.0015 M sodium citrate / 0.1% sodium dodecyl sulfate at 50°C; (2) employ a denaturing agent such as formamide during hybridization, for example, 50% (v / v) formamide with 750 mM sodium chloride, 75 mM sodium citrate at pH 6.5 with 0.1% bovine serum albumin / 0.1% polysucrose / 0.1% polyvinylpyrrolidone / 50 mM sodium phosphate buffer; or (3) employ 50% formamide, 5x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.5) at 42°C. 6.8), 0.1% sodium pyrophosphate, 5x Denhardt's solution, sonicated salmon sperm DNA (50 μg / ml), 0.1% SDS and 10% dextran sulfate, washes in 0.2x SSC (sodium chloride / sodium citrate) at 42° C. and in 50% formamide at 55° C., followed by a high stringency wash consisting of 0.1x SSC containing EDTA at 55° C. The skilled artisan will recognize how to adjust temperature, ionic strength, etc. as needed to accommodate factors such as probe length.
[0151] Those of ordinary skill in the art will appreciate that, due to the degeneracy of the genetic code, there are many nucleotide sequences encoding polypeptides as described herein. Some of these polynucleotides have minimal homology to the nucleotide sequence of any natural gene. However, the disclosure specifically contemplates polynucleotides that vary due to differences in codon usage. Further, alleles of genes comprising the polynucleotide sequences provided herein are within the scope of the disclosure. Alleles are endogenous genes that change due to one or more mutations of nucleotides, such as deletions, additions and / or substitutions. The resulting mRNA and protein may, but need not, have a changed structure or function. Standard techniques (such as hybridization, amplification and / or database sequence comparisons) can be used to identify alleles.
[0152] Can use chemical synthesis, recombination method or PCR to obtain polynucleotide of the present disclosure.The method of chemical polynucleotide synthesis is well-known in the art and does not need to be described in detail in this article.Those skilled in the art can use the sequence provided by this article and commercial DNA synthesizer to produce the desired DNA sequence.
[0153] In order to prepare polynucleotides using recombinant methods, the polynucleotides including the desired sequence can be inserted into a suitable vector, and then the vector can be introduced into a suitable host cell for replication and amplification, as further described herein. The polynucleotides can be inserted into a host cell by any means known in the art. Exogenous polynucleotides are introduced to transform cells by direct uptake, endocytosis, transfection, F-mating or electroporation. Once introduced, the exogenous polynucleotides can be maintained in the cell as a non-integrated vector (such as a plasmid) or integrated into the host cell genome. The polynucleotides amplified in this way can be separated from the host cell by methods well known in the art. See, for example, Sambrook et al., 1989.
[0154] Alternatively, PCR allows the replication of a DNA sequence. PCR techniques are well known in the art and are described, for example, in U.S. Pat. Nos. 4,683,195, 4,800,159, 4,754,065, and 4,683,202 and in PCR: The Polymerase Chain Reaction, Mullis et al., eds., Birkauswer Press, Boston, 1994.
[0155] RNA can be obtained by using the isolated DNA in a suitable vector and inserting it into a suitable host cell. When the cell replicates and the DNA is transcribed into RNA, the RNA can then be isolated using methods well known to those skilled in the art, for example, as described above by Sambrook et al., 1989.
[0156] Suitable cloning vectors can be constructed according to standard techniques or can be selected from a large number of cloning vectors available in the art. Although the cloning vector selected may be different according to the host cell to be used, useful cloning vectors will usually have the ability of self-replication, can have a single target for a specific restriction endonuclease and / or can carry the gene of a marker that can be used to select a clone containing a vector. Suitable examples include plasmids and bacterial viruses, such as pUC18, pUC19, Bluescript (such as pBS SK+) and derivatives thereof, mp18, mp19, pBR322, pMB9, ColE1, pCR1, RP4, phage DNA and shuttle vectors, such as pSA3 and pAT28. These and many other cloning vectors can be obtained from commercial suppliers, such as BioRad, Strategene and Invitrogen.
[0157] An expression vector is typically a replicable polynucleotide construct containing a polynucleotide according to the present disclosure. This means that the expression vector must be replicable in a host cell as an episome or as a component of chromosomal DNA. Suitable expression vectors include, but are not limited to, plasmids, viral vectors, including adenoviruses, adeno-associated viruses, retroviruses, cosmids, and PCT publications disclosed in WO 87 / 04462. Vector components may typically include, but are not limited to, one or more of the following: a signal sequence; an origin of replication; one or more marker genes; suitable transcription control elements (such as promoters, enhancers, and terminators). For expression (i.e., translation), one or more translation control elements, such as ribosome binding sites, translation start sites, and stop codons, are also typically required.
[0158] The vector containing the polynucleotide of interest can be introduced into the host cell by any of a variety of appropriate means, including electroporation; transfection using calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran or other substances; microprojectile bombardment; lipofection; and infection (e.g., where the vector is an infectious agent such as vaccinia virus). The choice of the vector or polynucleotide to be introduced will generally depend on the characteristics of the host cell.
[0159] The polynucleotide encoding the polypeptide (e.g., a chimeric switch receptor, a chimeric antigen receptor, or a chimeric cytokine receptor) can be present in an expression cassette or expression vector (e.g., a plasmid for introduction into a bacterial host cell, or a viral vector such as a baculovirus vector for transfection of an insect host cell, or a plasmid or viral vector such as a lentivirus for transfection of a mammalian host cell). In some embodiments, the polynucleotide or vector may comprise a nucleic acid sequence encoding a ribosomal skipping sequence, such as, but not limited to, a sequence encoding a 2A peptide. The 2A peptide identified in the aphthous virus subgroup of picornaviruses causes the ribosome to "jump" from one codon to the next without forming a peptide bond between the two amino acids encoded by the codon (see, e.g., Donnelly and Elliott 2001; Atkins, Wills et al. 2007; Doronina, Wu et al. 2008). "Codon" means three nucleotides on an mRNA (or on the sense strand of a DNA molecule) that are translated by the ribosome into one amino acid residue. Therefore, when the polypeptide is separated by the 2A oligopeptide sequence (P2A sequence) in the frame, the two polypeptides can be synthesized from a single continuous open reading frame in imRNA. Such ribosome jumping mechanisms are well known in the art, and are known to be used by several vectors to express several proteins encoded by a single messenger RNA. In some embodiments, the 2A encoding nucleotide sequence is located between the nucleic acid sequences encoding CAR (e.g., DLL3 CAR) as disclosed herein and CCR (e.g., inducible CCR or constitutive CCR) as disclosed herein; in some embodiments, in the preparation of engineered immune cells as disclosed herein, the polynucleotides encoding CAR and CCR are incorporated into the TRAC locus of immune cells. In some embodiments, the nucleic acid sequence encoding CCR is located at 5' of the nucleic acid sequence encoding CAR. In some embodiments, the nucleic acid sequence encoding CAR is located at 5' of the nucleic acid sequence encoding CCR.
[0160] In order to guide the transmembrane polypeptide into the secretory pathway of the host cell, in some embodiments, a secretion signal sequence (also referred to as a leader sequence, signal peptide, pre-prosequence or presequence) is provided in the polynucleotide sequence or the vector sequence. The secretion signal sequence is operably connected to the transmembrane nucleic acid sequence, that is, the two sequences are connected in the correct reading frame and are positioned to guide the newly synthesized polypeptide into the secretory pathway of the host cell. The secretion signal sequence is usually located at the 5' of the nucleic acid sequence encoding the polypeptide of interest, but some secretion signal sequences may be located at other places of the nucleic acid sequence of interest (see, for example, Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830). Those skilled in the art will recognize that, in view of the degeneracy of the genetic code, there may be considerable sequence variation in these polynucleotide molecules. In some embodiments, the nucleotide sequence of the present disclosure is codon optimized for expression in mammalian cells, preferably for expression in human cells. Codon optimization refers to exchanging codons that are typically rare in highly expressed genes of a given species with codons that are typically common in highly expressed genes of such species in the sequence of interest, such codons encoding the same amino acid as the codon being exchanged.
[0161] Provided herein are methods for preparing immune cells for immunotherapy. In some embodiments, the method comprises introducing a chimeric switch receptor as disclosed herein into one or more immune cells, or introducing a polynucleotide encoding a chimeric switch receptor, and amplifying the cells. In some embodiments, the disclosure relates to a method for engineering immune cells, the method comprising: providing immune cells, and expressing at least one chimeric switch receptor on the cell surface. In some embodiments, the method comprises: transfecting a cell with at least one polynucleotide encoding a chimeric switch receptor, and expressing at least one polynucleotide in the cell.
[0162] In some embodiments, the polynucleotide encoding the chimeric switch receptor is present in one or more expression vectors for stable expression in the cell. In some embodiments, the polynucleotide is present in a viral vector for stable expression in the cell. In some embodiments, the viral vector can be, for example, a lentiviral vector or an adenoviral vector.
[0163] In some embodiments, the polynucleotide encoding a polypeptide according to the present disclosure can be an mRNA that is directly introduced into a cell, for example, by electroporation. In some embodiments, the CytoPulse technology can be used to transiently permeabilize living cells to deliver materials into the cell. Parameters can be modified to determine conditions for high transfection efficiency and minimal mortality.
[0164] Also provided herein are methods for transfecting immune cells (e.g., T cells). Generally, any conventional method known to those of ordinary skill in the art can be used, such as introducing any one of RNA, DNA, or protein into cells by electroporation. See, for example, Luft and Ketteler, Journal of Biomolecular Screening 20(8):932(2015)(DOI:10.1177 / 1087057115579638). In some embodiments, the method includes: contacting T cells with RNA and applying an agile pulse sequence to the T cells, wherein the agile pulse sequence consists of: (a) electric pulses with a voltage ranging from about 2250 to 3000 V per centimeter; (b) a pulse width of 0.1 ms; (c) a pulse interval of about 0.2 to 10 ms between the electric pulses of steps (a) and (b); (d) electric pulses with a voltage ranging from about 2250 to 3000 V per centimeter, and a pulse width of about 100 ms and a pulse interval of about 100 ms between the electric pulse of step (b) and the first electric pulse of step (c); and (e) four electric pulses with a voltage of about 325 V, and a pulse width of about 0.2 ms and a pulse interval of 2 ms between each of the four electric pulses. In some embodiments, a method of transfecting a T cell comprises contacting the T cell with an RNA and applying an agile pulse sequence to the T cell, the agile pulse sequence comprising: (a) an electric pulse having a voltage of about 1600, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2400, 2450, 2500, 2600, 2700, 2800, 2900, or 3000 V per centimeter; (b) a pulse width of 0.1 ms; (c) and a pulse width of about 0.2, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ms between the electric pulses of steps (a) and (b). (d) a voltage ranging from about 2250 to 3000 V per centimeter, for example, one electric pulse of 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2400, 2450, 2500, 2600, 2700, 2800, 2900 or 3000 V per centimeter, and a pulse width of 100 ms and a pulse interval of 100 ms between the electric pulse of step (b) and the first electric pulse of step (c); and (e) 4 electric pulses with a voltage of about 325 V, and a pulse width of about 0.2 ms and a pulse interval of about 2 ms between each of the 4 electric pulses. Any value included in the value range described above is disclosed in the present application. The electroporation medium can be any suitable medium known in the art. In some embodiments, the conductivity of the electroporation medium ranges from about 0.01 to about 1.0 millisiemens.
[0165] In some embodiments, the method may further include the following steps: by inactivating at least one gene expressing, for example, but not limited to, components of TCR, targets of immunosuppressants, HLA genes, and / or immune checkpoint proteins (such as, for example, PDCD1 or CTLA-4) to genetically modify the cell. Gene inactivation is intended to prevent the gene of interest from being expressed in the form of functional protein. In some embodiments, the gene to be inactivated is selected from the group consisting of: for example, but not limited to, TCRα, TCRβ, CD52, GR, deoxycytidine kinase (DCK), TGF-B, and CTLA-4. In some embodiments, the method includes inactivating one or more genes by introducing a rare-cutting endonuclease capable of selectively inactivating genes by selective DNA cutting into the cell. In some embodiments, the rare-cutting endonuclease can be, for example, a transcription activator-like effector nuclease (TALE-nuclease) or a CRISPR-based endonuclease (e.g., Cas-9 or Cas12a).
[0166] In another aspect, the step of genetically modifying cells may include: modifying immune cells (e.g., T cells) by inactivating at least one gene expressing an immunosuppressant target, and optionally amplifying cells in the presence of an immunosuppressant. An immunosuppressant is an agent that suppresses immune function by one of several mechanisms of action. An immunosuppressant can reduce the degree and / or intensity of an immune response. Non-limiting examples of immunosuppressants include calcineurin inhibitors, rapamycin targets, interleukin-2 α-chain blockers, inosine monophosphate dehydrogenase inhibitors, dihydrofolate reductase inhibitors, corticosteroids, and immunosuppressive antimetabolites. Some cytotoxic immunosuppressants work by inhibiting DNA synthesis. Other cytotoxic immunosuppressants can work by activating T cells or by inhibiting the activation of helper cells. According to the method disclosed herein, it is allowed to confer, for example, T cell immunosuppression resistance to carry out immunotherapy by inactivating the target of the immunosuppressant in T cells. As non-limiting examples, the target of the immunosuppressant may be a receptor for the immunosuppressant, such as, but not limited to, CD52, glucocorticoid receptor (GR), FKBP family gene members, and cyclophilin family gene members.
[0167] The present disclosure provides a method for preparing an engineered immune cell disclosed herein, for example, an engineered immune cell expressing a chimeric switch receptor and optionally further expressing CAR or CAR and CCR. The present disclosure also provides a composition comprising such engineered immune cells prepared by the disclosed method. The present disclosure further provides a method of treatment, which includes administering a cell and a composition comprising a cell. The methods and compositions provided herein can be used to improve the therapeutic efficacy of engineered immune cells (e.g., engineered T cells, such as CAR-T cells).
[0168] One or more proteins or polypeptides, such as chimeric polypeptides disclosed herein (e.g., chimeric switch receptors), CARs, and CCRs can be synthesized in situ in cells after one or more polynucleotide constructs encoding proteins are introduced into cells. Alternatively, the polypeptide can be produced extracellularly and then introduced into cells. The method of introducing a polynucleotide construct into a cell is known in the art. In some embodiments, a stable transformation method can be used to integrate a polynucleotide construct into the genome of a cell. In other embodiments, a transient transformation method can be used to transiently express a polynucleotide construct and a polynucleotide construct that is not integrated into the genome of a cell. In other embodiments, a viral-mediated method can be used. Polynucleotides can be introduced into cells by any suitable means, such as recombinant viral vectors (e.g., retroviruses, including slow viruses, adenoviruses), liposomes, etc. Transient transformation methods include, but are not limited to, for example, microinjection, electroporation, or particle bombardment. Polynucleotides can be contained in a vector, such as a plasmid vector or a viral vector.
[0169] In some embodiments, the engineered immune cells (e.g., T cells) disclosed herein include at least one chimeric polypeptide disclosed herein (e.g., chimeric switch receptor) and other target polypeptides such as CAR and CCR. Engineered immune cells (e.g., T cells) can be further modified, for example, genetically engineered to express reduced levels of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT, and TCRα (such as TCRα, TRAC constant regions) in any one or more. In some embodiments, the polynucleotides or vectors encoding chimeric polypeptides (e.g., chimeric switch receptors), CARs, and / or CCRs are introduced into cells to also destroy the expression of any one or more of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT, and TCRα. In some embodiments, polynucleotides or vectors encoding chimeric polypeptides (e.g., chimeric switch receptors), CARs, and / or CCRs are introduced into the genome of engineered immune cells by site-specific integration (SSI) at one or more specific genetic loci. In some embodiments, one or more genetic loci can be, for example, but not limited to, one or more of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT, and TCR a (such as TRAC). In certain embodiments, a polynucleotide or vector encoding a chimeric polypeptide (e.g., a chimeric switch receptor) is introduced into the CD52 locus. In certain embodiments, a polynucleotide or vector encoding a chimeric switch receptor is introduced into any one of the PD1, TIM3, CISH, cbl-b, or TIGIT loci. In certain embodiments, a polynucleotide encoding CAR and / or CCR is introduced into the TRAC locus. In certain embodiments, a polynucleotide encoding CAR and / or CCR is introduced into the CD52 locus.
[0170] In some embodiments of engineered immune cells such as T cells provided herein, the CAR expressed by the cell may include an extracellular ligand binding domain (e.g., a single-chain variable fragment (scFv)), a transmembrane domain, and an intracellular signaling domain. In some embodiments, the extracellular ligand binding domain, the transmembrane domain, and the intracellular signaling domain are in one polypeptide, i.e., in a single chain. Multi-chain CAR and polypeptides are also provided herein. In some embodiments, the multi-chain CAR includes: a first polypeptide containing a transmembrane domain and at least one extracellular ligand binding domain, and a second polypeptide containing a transmembrane domain and at least one intracellular signaling domain, wherein the polypeptides are assembled together to form a multi-chain CAR.
[0171] The extracellular ligand binding domain of CAR specifically binds to the target of interest. In some embodiments, the target of interest can be any molecule of interest, including, for example, but not limited to BCMA, EGFRvIII, Flt-3, WT-1, CD20, CD23, CD30, CD38, CD70, CD33, CD133, WT1, TSPAN10, MHC-PRAME, Liv1, ADAM10, CHRNA2, LeY, NKG2D, CS1, CD44v6, ROR1, CD19, clotrimazole-18.2 (clotrimazole), TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α, TNF-α -18A2 or claudin 18 isoform 2), DLL3 (delta-like protein 3, Drosophila delta homolog 3, δ3), Muc17, Muc3, Muc3, Muc16, FAPα (fibroblast activation protein alpha), Ly6G6D (lymphocyte antigen 6 complex locus protein G6d, c6orf23, G6D, MEGT1, NG25), RNF43 (E3 ubiquitin protein ligase RNF43, RING finger protein 43), specifically including the human form of any one of the exemplary targets listed.
[0172] In some embodiments, the extracellular ligand binding domain of CAR comprises scFv, which comprises a light chain variable (VL) region and a heavy chain variable (VH) region of a target antigen-specific monoclonal antibody connected by a flexible linker. Single-chain variable region fragments are prepared by connecting light chain and / or heavy chain variable regions using short connecting peptides (Bird et al., Science 242: 423-426, 1988). An example of a connecting peptide is a GS linker with an amino acid sequence (GGGGS) 4 (SEQ ID NO: 159), which bridges about 3.5 nm between the carboxyl terminus of one variable region and the amino terminus of another variable region. Other sequence linkers have been designed and used (Bird et al., 1988, supra). Generally, the linker can be a short flexible polypeptide and preferably comprises about 20 or less amino acid residues. Then the linker can be modified for additional functions, such as attaching drugs or attaching to a solid phase carrier. Single-chain variants can be produced by recombination or synthesis. For the synthetic production of scFv, an automatic synthesizer can be used. For the recombinant production of scFv, a suitable plasmid or other vector containing a polynucleotide encoding the scFv can be introduced into a suitable host cell (e.g., a eukaryotic cell such as a yeast, plant, insect or mammalian cell, or a prokaryotic cell such as Escherichia coli). The polynucleotide encoding the scFv of interest can be prepared by conventional operations such as ligation of the polynucleotides. The resulting scFv can be isolated using standard protein purification techniques known in the art.
[0173] As disclosed herein, the intracellular signaling domain of CAR is responsible for intracellular signaling after the extracellular ligand binding domain of CAR binds to the target, resulting in activation of immune cells and immune response. The intracellular signaling domain can activate at least one of the normal effector functions of immune cells expressing CAR. For example, the effector function of T cells can be cytolytic activity or auxiliary activity (including secretion of cytokines).
[0174] In some embodiments, the intracellular signaling domain used in CAR can be, for example, but not limited to, cytoplasmic sequences of T cell receptors and co-receptors, and any derivatives or variants of these sequences and any synthetic sequences with the same functional capabilities, the T cell receptors and co-receptors act synergistically after antigen receptor engagement to initiate signal transduction. The intracellular signaling domain includes two different types of cytoplasmic signaling sequences: cytoplasmic signaling sequences that initiate antigen-dependent primary activation, and cytoplasmic signaling sequences that act in an antigen-independent manner to provide secondary or costimulatory signals. The main cytoplasmic signaling sequence can include a signaling motif known as an immunoreceptor tyrosine-based activation motif or ITAM. ITAM is a well-defined signaling motif found in the cytoplasmic tail region of various receptors that act as binding sites for syk / zap70-like tyrosine kinases. Examples of ITAM used in the present disclosure may include those derived from TCR zeta, FcR γ, FcR β, FcR ε, CD3 γ, CD3 δ, CD3 ε, CD5, CD22, CD79a, CD79b and CD66d as non-limiting examples. In some embodiments, the intracellular signaling domain of CAR includes a CD3 zeta signaling domain. In some embodiments, the intracellular signaling domain of CAR of the present disclosure includes or further includes a domain of a costimulatory molecule.
[0175] In some embodiments, the intracellular signaling domain of the CAR of the present disclosure includes a portion of a co-stimulatory molecule selected from the group consisting of fragments of 4-1BB (GenBank: AAA53133) and CD28 (NP_006130 and isoforms thereof).
[0176] CAR is expressed on the surface membrane of the cell. Therefore, CAR may include a transmembrane domain. Suitable transmembrane domains of CAR disclosed herein have the following capabilities: (a) expressed on the cell surface, such as expressed on the surface of immune cells, such as, for example, but not limited to, lymphocytes (e.g., T cells) or natural killer (NK) cells; and (b) interacting with the ligand binding domain and the intracellular signaling domain to instruct the cellular response of immune cells to predetermined target cells. The transmembrane domain may be derived from a natural or synthetic source. The transmembrane domain may be derived from any membrane-bound or transmembrane protein. As a non-limiting example, a transmembrane polypeptide may be a domain of a T cell receptor, such as α, β, γ or δ; a polypeptide constituting a CD3 complex; an IL-2 receptor such as p55 (α chain), p75 (β chain or γ chain); an Fc receptor, specifically a subunit chain of Fcγ receptor III; or a CD protein. Alternatively, the transmembrane domain may be synthetic and may mainly include hydrophobic residues, such as leucine and valine. In some embodiments, the membrane-spanning domain is derived from human CD8 α chain (e.g., NP_001139345.1). The membrane-spanning domain may further include a stem domain between the extracellular ligand binding domain and the membrane-spanning domain. The stem domain may include up to 300 amino acids, such as 10 to 100 amino acids or 25 to 50 amino acids. The stem region may be derived from all or part of a naturally occurring molecule, such as all or part of the extracellular region derived from CD8, CD4 or CD28, or all or part of an antibody constant region. Alternatively, the stem domain may be a synthetic sequence corresponding to a naturally occurring stem sequence, or may be a fully synthetic stem sequence. In some embodiments, the stem domain is a part of human CD8 α chain (e.g., NP_001139345 and its isotype). In another specific embodiment, the membrane-spanning domain includes a part of human CD8 α chain. In some embodiments, the CAR disclosed herein may include an extracellular ligand binding domain, a CD3ζ signaling domain, and a 4-1BB signaling domain that specifically binds to BCMA, a CD8α human stem domain, and a transmembrane domain. In some embodiments, CAR can be introduced into immune cells as a transgene through a vector such as a plasmid vector. In some embodiments, a vector such as a plasmid vector may also contain, for example, a selection marker for identifying and / or selecting cells that accept the vector.
[0177] Chimeric switch receptors, CAR and CCR polypeptides can be synthesized in situ in cells after the polynucleotides encoding these polypeptides are introduced into cells. Alternatively, one or more of the polypeptides can be produced extracellularly and then introduced into cells. The method of introducing a polynucleotide construct into a cell is known in the art. In some embodiments, a stable transformation method can be used to integrate a polynucleotide construct into the genome of a cell. In other embodiments, a transient transformation method can be used to transiently express a polynucleotide construct and a polynucleotide construct that is not integrated into the genome of a cell. In other embodiments, a viral-mediated method can be used. Polynucleotides can be introduced into cells by any suitable means, such as recombinant viral vectors (e.g., retroviruses (e.g., lentiviruses), adenoviruses), liposomes, etc. Transient transformation methods include, but are not limited to, for example, microinjection, electroporation, or particle bombardment. Polynucleotides can be included in a vector, such as a plasmid vector or a viral vector.
[0178] Also provided herein are immune cells, such as T cells, such as isolated T cells obtained according to any of the methods described herein. Any immune cell capable of expressing heterologous DNA can be used for the purpose of expressing chimeric switch receptors, target CARs and CCR polypeptides, and further for engineering to express reduced levels of, for example, CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT and / or TCRa or eliminate their expression. In some embodiments, immune cells are T cells. In some embodiments, immune cells can be derived from, for example, but not limited to, stem cells. Stem cells can be adult stem cells, non-human embryonic stem cells, more specifically non-human stem cells, cord blood stem cells, progenitor cells, bone marrow stem cells, induced pluripotent stem cells, totipotent stem cells or hematopoietic stem cells. Representative human cells are CD34+ cells. The isolated cells can also be dendritic cells, killer dendritic cells, mast cells, NK cells, B cells or T cells selected from the group consisting of: inflammatory T lymphocytes, cytotoxic T lymphocytes, regulatory T lymphocytes or helper T lymphocytes. In some embodiments, the cell can be derived from a group consisting of CD4+T lymphocytes and CD8+T lymphocytes. In some embodiments, immune cells (e.g., T cells, such as isolated T cells) are further modified by methods described herein (e.g., known gene editing techniques, which use, for example, TALEN, CRISPR / Cas9 or megaTAL nucleases to partially or completely delete or destroy one or more genetic loci as needed), such as genetically engineered, such that they express reduced levels of, for example, CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT, and TCRa relative to comparable cells that are not engineered to express reduced or altered levels of corresponding proteins. One or more.
[0179] The amino acid sequences of the components of the chimeric switch receptors as disclosed herein are provided in Table 1.
[0180] Table 1. Exemplary single module amino acid sequences
[0181]
[0182]
[0183]
[0184] The nucleotide sequences of the components of the chimeric switch receptors as disclosed herein are provided in Table 2.
[0185] Table 2. Exemplary single module-DNA sequences
[0186]
[0187]
[0188]
[0189]
[0190]
[0191] The amino acid sequences of the full-length chimeric switch receptors as disclosed herein are provided in Table 3.
[0192] Table 3: Exemplary full length constructs - amino acid sequences
[0193]
[0194]
[0195]
[0196]
[0197]
[0198]
[0199]
[0200]
[0201]
[0202] The nucleotide sequences of the full-length chimeric switch receptors as disclosed herein are provided in Table 4.
[0203] Table 4
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
[0222]
[0223]
[0224]
[0225] The engineered immune cells provided herein may include one or more mimicking epitope sequences that can sort cells to enrich engineered cells as described herein, e.g., express antigen binding proteins, and / or provide a safety switch mechanism to inactivate immune cells after the cells are administered to a patient or recipient, e.g., to limit the cell population of side effects. Such mimicking epitope sequences and their use in cell sorting and as safety switches are known in the art and are described, e.g., in US2018 / 0002435, which is incorporated herein by reference in its entirety.
[0226] Before amplification and genetic modification, cell sources can be obtained from a subject by a variety of non-limiting methods. Cells can be obtained from a plurality of non-limiting sources, and the non-limiting sources include peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from infection site, ascites, pleural effusion, spleen tissue and tumor. In some embodiments, any number of T cell lines available and known to those skilled in the art can be used. In some embodiments, cells can be derived from healthy donors, from subjects diagnosed with cancer or from subjects diagnosed with infection. In some embodiments, cells can be part of a mixed cell colony presenting different phenotypic characteristics.
[0227] Also provided herein is a cell line obtained from a modified, e.g., transformed or engineered immune cell, e.g., engineered T cell, according to any method described herein. In some embodiments, a cell line prepared from or derived from an engineered immune cell (e.g., engineered T cell) according to the disclosure includes a chimeric polypeptide (e.g., chimeric switch receptor) encoding the present invention and an optional CAR and / or CCR polynucleotide; The cell line is also optionally modified or engineered, e.g., genetically modified to not express or express (e.g., functionally express) reduced levels of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT, and TCRa.
[0228] Immune cells (e.g., T cells) of the present disclosure can be activated and expanded before or after cell modification using methods as generally described, for example, but not limited to, methods in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041 and U.S. Patent Application Publication No. 20060121005. Immune cells (e.g., T cells) can be expanded in vitro or in vivo. In general, immune cells of the present disclosure can be expanded, for example, by contacting with agents that stimulate the CD3 TCR complex and co-stimulatory molecules on the surface of immune cells to generate activation signals for the cells. For example, chemicals such as calcium ionophore A23187, phorbol 12-myristate 13-acetate (PMA), or mitogenic lectin-like phytohemagglutinin (PHA) can be used to generate activation signals for immune cells (e.g., T cells).
[0229] In some embodiments, a T cell population can be stimulated in vitro by contact with, for example, an anti-CD3 antibody or an antigen binding fragment thereof or an anti-CD2 antibody immobilized on a surface or with a protein kinase C activator (e.g., bryostatin) conjugated to a calcium ionophore. In order to co-stimulate auxiliary molecules on the surface of T cells, a ligand that binds to the auxiliary molecule is used. For example, under conditions suitable for stimulating the proliferation of T cells, a T cell population can be contacted with an anti-CD3 antibody and an anti-CD28 antibody. Conditions suitable for T cell culture include an appropriate culture medium (e.g., minimal essential medium, RPMI medium 1640 or X-VIVO TM 5 (Lonza), the medium may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine serum or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, GM-CSF, IL-10, IL-2, IL-15, TGFβ and TNF or any other additives for cell growth known to those skilled in the art. Other additives for cell growth include, but are not limited to, surfactants, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. The culture medium may comprise RPMI 1640 (as described herein), AIM V, DMEM, MEM, α-MEM, F-12, X-VIVO TM 10. X-VIVO TM 15 and X-VIVOTM 20. OpTmizer TM , and amino acids, sodium pyruvate and vitamins are added, serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones and / or cytokines sufficient to grow and expand T cells. Antibiotics (e.g., penicillin and streptomycin) are only included in experimental cultures and not in cell cultures to be injected into the subject. Target cells are maintained under conditions required to support growth, such as an appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5% CO2). Immune cells (e.g., T cells) exposed to different stimulation times may exhibit different
[0230] In some embodiments, the cells of the present disclosure can be expanded by co-culturing with tissues or cells. The cells can also be expanded in vivo, for example in the blood of a subject after the cells are administered to the subject.
[0231] In another aspect, the present disclosure provides compositions (such as pharmaceutical compositions) comprising any of the cells (e.g., engineered immune cells) disclosed herein. In some embodiments, the composition comprises an engineered immune cell (e.g., an engineered T cell) containing a polynucleotide encoding a chimeric polypeptide (e.g., a chimeric switch receptor) as disclosed herein, or a cell population (e.g., comprising about 1x10 4 About 1x10 10 A cell population of engineered immune cells provided herein) and one or more pharmaceutically acceptable carriers or excipients.
[0232] In some embodiments, the primary cells isolated from the donor are engineered as described herein to provide a cell population, wherein a subpopulation of the resulting cells (e.g., a ratio less than 100%, such as 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%) includes all desired modifications. Such resulting populations including mixtures of cells comprising all modifications and cells not comprising all modifications can be used in the methods of treatment of the present disclosure and for preparing compositions of the present disclosure. Alternatively, the cell population ("starting population") can be manipulated by known methods, such as cell sorting and / or amplification of cells with the desired modifications, to provide a cell population enriched for those cells containing one or more desired modifications (e.g., cells enriched for expression of the desired chimeric switch receptor protein and / or cells enriched for expression of one or more of CAR and CCR, wherein the polynucleotide encoding the chimeric switch receptor is inserted at the CD70 locus, CD52 locus, PD1 locus, TIM3 locus, CISH locus, TIGIT locus or cbl-b locus, and wherein the polynucleotide encoding CAR and optional CCR is inserted at the TRAC locus), that is, a cell population containing a higher percentage of such modified or engineered cells than the starting population. Then, the enriched modified cell population can be used in the methods of treatment disclosed herein, and for preparing, for example, compositions disclosed herein. In some embodiments, the enriched cell colony contains or contains at least, for example, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% cells with one or more modifications. In other embodiments, the cell ratio in the enriched cell colony including one or more modifications is at least 30% higher than the cell ratio in the starting cell colony including the desired modification.
[0233] Treatment
[0234] The engineered immune cells (e.g., engineered T cells) obtained by the methods described herein or cell lines derived from such immune cells or T cells can be used as drugs or for the preparation of drugs. In some embodiments, such drugs can be used to treat diseases such as viral diseases, bacterial diseases, cancers, inflammatory diseases, immune diseases, or aging-related diseases. In some embodiments, the cancer can be selected from the group consisting of: gastric cancer, sarcoma, lymphoma (including non-Hodgkin's lymphoma), leukemia, head and neck cancer, thymic cancer, epithelial cancer, salivary cancer, liver cancer, stomach cancer, thyroid cancer, lung cancer, ovarian cancer, breast cancer, prostate cancer, esophageal cancer, pancreatic cancer, glioma, leukemia, multiple myeloma, renal cell carcinoma, bladder cancer, cervical cancer, choriocarcinoma, colon cancer, oral cancer, skin cancer, and melanoma. In some embodiments, the subject is a previously treated adult subject with locally advanced or metastatic melanoma, squamous cell head and neck cancer (SCHNC), ovarian cancer, sarcoma, or relapsed or refractory classical Hodgkin's lymphoma (cHL).
[0235] In some embodiments, engineered immune cells, such as engineered T cells, or cell lines derived from engineered immune cells, such as engineered T cells, according to the present disclosure can be used to prepare a medicament for treating a disorder in a subject in need thereof. In some embodiments, the disorder can be, for example, cancer, an autoimmune disorder, or an infection.
[0236] Also provided herein is a method for treating a subject. In some embodiments, the method includes administering or providing an engineered immune cell (e.g., engineered T cell) of the present disclosure to a subject in need. In some embodiments, the method includes administering an engineered immune cell (e.g., engineered T cell) of the present disclosure to a subject in need.
[0237] In some embodiments, the engineered immune cells of the present disclosure, such as engineered T cells, can undergo robust in vivo cell expansion and can last for an extended amount of time. The treatment methods disclosed herein can be ameliorative, curative, or preventive. The methods disclosed herein can be part of an autologous immunotherapy or part of an allogeneic immunotherapy treatment. The present disclosure is particularly applicable to allogeneic immunotherapy. Standard protocols can be used to convert engineered immune cells (e.g., engineered T cells) prepared from cells provided by a donor into non-alloreactive cells and propagated as needed to produce, for example, CAR-T cells expressing a chimeric switch receptor that can be administered to one or several subjects. This CAR-T cell therapy can be used as an allogeneic therapeutic product (e.g., ALLO CAR T TMtherapeutic products) utilization.
[0238] On the other hand, the present disclosure provides a method of inhibiting tumor growth or progression in a subject with a tumor, the method comprising administering to the subject an effective amount of engineered immune cells as described herein, such as engineered T cells. On the other hand, the present disclosure provides a method of inhibiting or preventing metastasis of cancer cells in a subject, the method comprising administering to a subject in need an effective amount of engineered immune cells as described herein, such as engineered T cells. On the other hand, the present disclosure provides a method of inducing tumor regression in a subject with a tumor, the method comprising administering to the subject an effective amount of engineered immune cells as described herein, such as engineered T cells.
[0239] In some embodiments, the immune cells (eg, T cells) provided herein can be administered parenterally to a subject. In some embodiments, the subject is a human.
[0240] In some embodiments, the method may further include administering an effective amount of a second therapeutic agent. In some embodiments, the second therapeutic agent is, for example, crizotinib, palbociclib, anti-CTLA4 antibody, anti-4-1BB antibody, PD-1 antibody or PD-L1 antibody.
[0241] Also provided herein is the use of any of the engineered immune cells (eg, T cells) provided herein in the preparation of a medicament for treating cancer in a subject in need thereof or inhibiting tumor growth or progression.
[0242] In certain embodiments, the functional expression level of one or more of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT, and TCRα in the engineered immune cells of the present disclosure is reduced or at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% relative to the corresponding expression level in a comparable but not so genetically modified engineered immune cell. The expression level can be determined by any known method such as FACS or MAC. In some embodiments, the engineered immune cells disclosed herein functionally express any one or more of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT, and TCRa at a level no greater than 75%, no greater than 50%, no greater than 25%, no greater than 10%, or 0% of the expression level of an unengineered immune cell (otherwise identical to an engineered immune cell, e.g., comprising the same components as an engineered immune cell). In some embodiments, both alleles of a gene are knocked out, such that the gene expression level of the engineered immune cells disclosed herein is 0% of the gene expression level of the corresponding unengineered cell. In some embodiments, one of the two alleles of a gene is knocked out, such that the gene expression level of the engineered immune cells disclosed herein is 50% or about 50% of the gene expression level of the corresponding unengineered cell (e.g., if a compensatory mechanism results in higher than normal expression of the remaining allele). As described herein, if, for example, expression is reduced by some means other than knockout, a moderate expression level may be observed.
[0243] In some embodiments, the expression level of one or more of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT and TCRα in the engineered cells of the present disclosure can be directly measured by measuring the gene products of the cells and their characteristics using standard techniques known to those skilled in the art (e.g., RT-qPCR, nucleic acid sequencing, antibody staining, or some combination of techniques). In some embodiments, the functional expression level of one or more of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT and TCRα is measured by standard techniques known in the art (e.g., flow cytometry). These measurements can be compared with corresponding measurements made on comparable cells that have not been engineered to reduce the corresponding functional expression levels. In a cell population that includes engineered cells of the invention (e.g., engineered immune cells), a pooled sample of the material being measured (e.g., RNA or protein or cells) will reflect the fact that some cells do not express the gene of interest, having both alleles knocked out, e.g., some cells express 50% or about 50% of the gene of interest, having only one allele knocked out, and some cells express normal levels of the gene of interest if the population includes unengineered cells.
[0244] The functional expression level of one or more of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT, and TCRα expression in the engineered immune cells of the present disclosure can also be determined, for example, by measuring the extent to which the engineered immune cells survive in the presence of effector cells (e.g., T cells or NK cells) compared to the extent to which non-engineered but otherwise comparable (e.g., identical) immune cells survive under the same conditions.
[0245] In some embodiments, the treatments disclosed herein can be combined with one or more anti-cancer therapies selected from the group consisting of surgery, antibody therapy, chemotherapy, cytokine therapy, dendritic cell therapy, gene therapy, hormone therapy, laser therapy, and radiation therapy.
[0246] In some embodiments, treatment can be administered to subjects undergoing immunosuppressive therapy. In fact, the present disclosure can rely on cells or cell populations that are resistant to at least one immunosuppressant due to gene inactivation of receptors encoding such immunosuppressants. In this regard, immunosuppressive therapy can facilitate the selection and expansion of T cells according to the present disclosure in a subject.
[0247] Administration of cells or cell populations according to the present disclosure can be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein can be administered to a subject subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection or intraperitoneally. In one embodiment, the cell compositions of the present disclosure are administered by intravenous injection.
[0248] In some embodiments, administration of cells or cell populations according to the present disclosure may include administration of, for example, about 10 3 or 10 4 About 10 9 cells / kg body weight, including all integer values within those ranges, or a composition as disclosed herein comprising an engineered immune cell as disclosed herein. In some embodiments, administration of a cell or cell population may include administration of about 10 cells / kg body weight. 5 to about 10 6 cells, including all integer values within these ranges, or 0.1 × 10 cells / kg body weight 6 Up to 5×10 6 The engineered immune cells of the present invention, or a total of 0.1×10 8 Up to 5×10 8 Engineered immune cells. Cells or cell colonies can be administered in one or more doses. In some embodiments, an effective amount of cells can be administered as a single dose. In some embodiments, an effective amount of cells can be administered as more than one dose over a period of time. The administration time is within the discretion of the attending physician and depends on the clinical condition of the subject. Cells or cell colonies can be obtained from any source, such as a blood bank or a donor. Although individual needs are different, the determination of the optimal range of the effective amount of a given cell type for a specific disease or condition is within the technical scope of the art. An effective amount means the amount that provides a therapeutic or preventive benefit. The dosage administered will depend on the age, health and weight of the recipient, the type of concurrent treatment (if any), the frequency of treatment, and the nature of the desired effect. In some embodiments, an effective amount of cells or a composition including those cells is administered parenterally. In some embodiments, administration can be intravenous administration. In some embodiments, administration can be performed directly by injection into the tumor.
[0249] In some embodiments of the present disclosure, cells (e.g., engineered immune cells) as disclosed herein are administered to a subject in conjunction with (e.g., before, simultaneously with, or after) any number of related therapeutic modalities, including, but not limited to, treatment with agents such as monoclonal antibody therapy, CCR2 antagonists (e.g., INC-8761), antiviral therapy, cidofovir and interleukin 2, cytarabine (also known as ARA-C), or nataliziimab treatment for MS subjects or efaliztimab treatment for psoriasis subjects or other treatments for PML subjects. In some embodiments, BCMA-specific CAR-T cells are administered to a subject in combination with one or more of the following: anti-PD-1 antibodies (e.g., nivolumab, pembrolizumab, anti-PD-L1 antibodies (e.g., avelumab, atezolizumab, or durvalumab), anti-OX40 antibodies, anti-4-1BB antibodies (e.g., Utolimumab), anti-MCSF antibodies, anti-GITR antibodies, and / or anti-TIGIT antibodies. In additional embodiments, the immune cells (e.g., T cells) of the present disclosure can be administered in combination with surgery, chemotherapy, radiation, immunosuppressants (such as cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, and FK506), antibodies, or other immune clearing agents (such as CAMPATH ( These drugs inhibit the calcium-dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit p70S6 kinase (rapamycin), which is important for growth factor-induced signaling (Henderson, Naya, et al. Immunology. 1991 Jul;73(3):316–321; Liu, Albers, et al. Biochemistry. 1992 Apr 28;31(16):3896-901; Bierer, Hollander, et al. Curr Opin Immunol. 1993 Jul;73(3):316–321; Liu, Albers, et al. Biochemistry. 1992 Apr 28;31(16):3896-901; Bierer, Hollander, et al. Curr Opin Immunol. 1993 Jul;73(3):316–321; Liu, Albers, et al. Biochemistry. 1992 Apr 28;31(16):3896-901; Bierer, Hollander, et al. Curr Opin Immunol. Opin Immunol. 1993 Oct;5(5):763-73). The intervals between different treatments can range from a few minutes (e.g., 1 to 360 minutes) to a few hours (e.g., up to 6, 12, 18 or 24 hours), a few days (e.g., up to 1 to 7 days) or a few weeks, such as up to 1, 2, 4, 8, 16 or 52 weeks.
[0250] In additional embodiments, the cell compositions of the present disclosure are administered to a subject in combination with (e.g., before, simultaneously with, or after) bone marrow transplantation, T cell ablation therapy using chemotherapeutic agents such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide, or antibodies such as CAMPATH. In some embodiments, the cell compositions of the present disclosure are administered after B cell ablation therapy (e.g., an agent reactive with CD20, e.g., Rituxan). For example, in one embodiment, a subject may undergo standard treatment, wherein high-dose chemotherapy is followed by a peripheral blood stem cell transplant. In certain embodiments, after the transplant, the subject receives an infusion of the expanded immune cells of the present disclosure. In some embodiments, the expanded cells are administered before or after surgery.
[0251] Reagent test kit
[0252] The present disclosure also provides a kit for the method of the present invention. The kit of the present disclosure includes one or more containers, and the one or more containers include a composition of the present disclosure or an immune cell of the present disclosure, such as a T cell or a cell colony including an immune cell of the present disclosure (such as an engineered T cell). In various embodiments, immune cells (such as T cells) include one or more polynucleotides encoding one or more of the required chimeric switch receptor protein and CAR and CCR as described herein, and are further engineered to express one or more of the CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT and TCR a of the reduced level as described herein. The kit further includes instructions for use according to any method of the present disclosure described herein. Typically, these instructions include a description of the administration of a composition, immune cell (e.g., T cell) or cell colony for the therapeutic treatment described above.
[0253] Instructions for use of kit components typically include information about dosages, dosing regimens, and routes of administration for the intended treatment. The container may be a unit dose, bulk package (e.g., multi-dose package), or subunit dose. The instructions provided in the kit of the present disclosure are typically written instructions on a label or package insert (e.g., paper included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
[0254] The kit of the present disclosure adopts suitable packaging. Suitable packaging includes but is not limited to vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), etc. It is also contemplated that packaging used in combination with a specific device (e.g., an inhaler, a nasal application device (e.g., a nebulizer), or an infusion device (e.g., a micropump)) is used. The kit can have a sterile access port (e.g., the container can be an intravenous bag or a vial with a stopper that can be pierced by a hypodermic needle). The container can also have a sterile inlet port (e.g., the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic needle). According to the present disclosure, at least one active agent in the composition is an immune cell (e.g., a T cell). The container can further include a second pharmaceutically active agent.
[0255] The kit may optionally provide additional components such as buffers, and interpretative information. Typically, the kit comprises a container and a label or package insert on or associated with the container.
[0256] Sorting and removal methods
[0257] In some embodiments, a method for in vitro sorting of immune cell populations is provided, wherein a subset of immune cell populations comprises an immune cell engineered to express one or more of CD70, CD52, PD1, TIM3, CISH, cbl-b, TIGIT, and TCRa at reduced levels and / or expressing a chimeric switch receptor and an antigen binding protein (eg, CAR). In various embodiments, the method includes contacting the immune cell population with a monoclonal antibody specific for an epitope unique to an engineered cell (eg, a mimic epitope, such as those provided in US2018 / 0002435) (eg, an epitope of an antigen binding protein or a mimic epitope incorporated into an antigen binding protein), and selecting immune cells bound to the monoclonal antibody to obtain a cell population enriched in an engineered immune cell expressing an antigen binding protein.
[0258] In some embodiments, the monoclonal antibody specific for the epitope is optionally conjugated to a fluorophore. In this embodiment, the step of selecting cells that bind to the monoclonal antibody can be accomplished by fluorescence activated cell sorting (FACS).
[0259] In some embodiments, the monoclonal antibody specific for the epitope is optionally conjugated to magnetic particles. In this embodiment, the step of selecting cells that bind to the monoclonal antibody can be accomplished by magnetic activated cell sorting (MACS).
[0260] In some embodiments, the mAb used in the method of sorting immune cells expressing the chimeric switch receptor and antigen binding protein (e.g., CAR) of the present disclosure is selected from alemtuzumab, ibritumomab tiuxetan, muromonab-CD3, tositumomab, abciximab, basiliximab, brentuximab, cetuximab, infliximab, rituximab, bevacizumab, certolizumab pegol, daclizumab, eculizumab, efalizumab, Gemtuzumab, natalizumab, omalizumab, palivizumab, ranibizumab, tosilimab, trastuzumab, vedolizumab, adalimumab, belimumab, canakinumab, denosumab, golimumab, ipilimumab, ofatumumab, panitumumab, QBEND-10 and / or ustekinumab. In some embodiments, the mAb is rituximab. In another embodiment, the mAb is QBEND-10.
[0261] In some embodiments, the CAR-expressing immune cell population obtained when using the method described above for in vitro sorting of immune cells expressing CAR comprises at least 70%, 75%, 80%, 85%, 90%, 95% of immune cells expressing CAR. In some embodiments, the CAR-expressing immune cell population obtained when using the method for in vitro sorting of immune cells expressing CAR comprises at least 85% of immune cells expressing CAR.
[0262] In some embodiments, the immune cell colonies expressing CAR obtained when using the method described above for in vitro sorting of immune cells expressing CAR are compared with the initial (unsorted) cell colonies, showing enhanced in vitro cytotoxic activity. In some embodiments, the in vitro cytotoxic activity increases by 10%, 20%, 30% or 50%. In some embodiments, the immune cells are T cells.
[0263] Immune cells expressing the chimeric switch receptor and CAR to be administered to the receptor can be enriched in vitro from the source population. Methods for expanding the source population can include using a combination of density centrifugation, immunomagnetic bead purification, affinity chromatography, and fluorescence activated cell sorting to select cells expressing antigens such as the CD34 antigen.
[0264] Flow cytometry can be used to quantify specific cell types within a cell population. Typically, flow cytometry is a method used to quantify components or structural features of cells, primarily by optical means. Since different cell types can be distinguished by quantitative structural features, flow cytometry and cell sorting can be used to count and sort cells of different phenotypes in a mixture.
[0265] Flow cytometry analysis involves two main steps: 1) labeling selected cell types with one or more labeled markers, and 2) determining the number of labeled cells relative to the total number of cells in the population. In some embodiments, the method of labeling cell types comprises binding a labeled antibody to a marker expressed by a specific cell type. The antibody can be labeled directly with a fluorescent compound or indirectly using, for example, a fluorescently labeled secondary antibody that recognizes the primary antibody.
[0266] In some embodiments, the method for sorting T cells expressing CAR is a magnetic activated cell sorting (MACS) method. MACS is a method for separating various cell populations according to cell surface antigens (CD molecules) by using superparamagnetic nanoparticles and columns. MACS can be used to obtain pure cell populations. Cells in a single cell suspension can be magnetically labeled with microbeads. The sample is applied to a column consisting of ferromagnetic spheres, which is covered with a cell-friendly coating that allows rapid and gentle separation of cells. Unlabeled cells pass through and magnetically labeled cells are retained in the column. The effluent can be collected as an unlabeled cell fraction. After the washing step, the column is removed from the separator, and the magnetically labeled cells are eluted from the column.
[0267] Detailed protocols for purifying specific cell populations (such as T cells) can be found in Basu S et al. (2010). (Basu S, Campbell HM, Dittel BN, Ray A. Purification of specific cell population by fluorescence activated cellsorting. Journal of Visualized Experiments (J. Vis. Exp.) (41): 1546).
[0268] Example
[0269] Embodiment 1: Design of chimeric switch receptors
[0270] The chimeric switch receptor can be a fusion protein comprising an extracellular domain and / or a transmembrane domain derived from an inhibitory receptor (e.g., PD1 or TGFbR2) fused to a transmembrane domain and / or an intracellular signaling domain derived from one or more co-stimulatory proteins (e.g., CD2, CD28, MyD88, DAP10, or ICOS). The chimeric switch receptor can compete with endogenous inhibitory receptors (e.g., PD1 or TGFbR) for ligand binding to disrupt immunosuppression and transmit a co-stimulatory signal in an environment enriched with PDL1 / 2 or TGFb.
[0271] In a chimeric switch receptor containing an extracellular domain derived from PD1, the extracellular domain can, for example, be a wild-type sequence, or be modified to bind a PD1 ligand with a higher affinity than wild-type PD1.
[0272] In a chimeric switch receptor containing an extracellular domain derived from TGFbR2 (also referred to herein as "BR2"), the extracellular domain can be, for example, a wild-type sequence, or modified, for example, by deleting 25 residues from the N-terminus of the wild-type sequence (dN25). The TGFbR2 N25 peptide can mediate the recruitment of TGFbR1, which may in turn interfere with the costimulatory signaling of the chimeric switch receptor. Deleting the N25 peptide eliminates TGFbR1 recruitment and can enhance chimeric switch receptor signaling.
[0273] In cases where the intracellular signaling domain does not have a transmembrane domain (e.g., MyD88), the non-dimerizing PD1 transmembrane domain can be used to minimize tonic signaling of the chimeric switch receptor.
[0274] A single intracellular co-stimulatory domain can be optimized to reduce the size of the vector cargo and / or enhance or modulate functional activity by removing non-signaling interfering sequences or negative regulatory sequences (e.g., CD2 short) or by mutating key residues involved in signal transduction (e.g., CD28.YMFM and CD28.AYAA, amino acid substitution variants of YMNM and PYAP of the CD28 intracellular domain, respectively). See Boucher et al., 2021, Cancer Immunology Res. 9:62.
[0275] Figure 1A and Figure 1B The domain structures of representative PD1 chimeric switch receptors and TGFbR2 chimeric switch receptors are shown.
[0276] Embodiment 2: Generation of T cells expressing the chimeric switch receptor alone or with the DLL3 CAR using lentiviral co-transduction
[0277] To generate T cells expressing the chimeric switch receptor alone or in combination with the DLL3 CAR, we first used EasySepTM Human T Cell Isolation Kit (StemCell) Primary human T cells were purified from LeukoPak (StemCell Technologies).
[0278] The activity of different chimeric switch receptors was tested alone or in combination with a CAR (e.g., a DLL3 CAR). The activity of CAR T cells expressing the DLL3 CAR clone 2G1 and co-expressing the CCR of the 15.1 construct or the CCR of the 15.3 construct was first evaluated. In the low stringency SHP-77 subcutaneous tumor model, 5x10 6 SHP-77 cells were injected subcutaneously into NSG mice (n=8 / group) and 5×10 6 CAR T cells. In these experiments, peripheral blood T cell numbers were analyzed by flow cytometry at days 71, 85, and 99 after implantation. Next, CAR T cells were tested in a high-stringency subcutaneous tumor model. In this model, 5x10 6 NCI-H82 cells were injected subcutaneously into NSG mice (n=10 / group) and 3×10 6 or 6x10 6 CAR T cells. Peripheral blood T cell numbers were analyzed by flow cytometry once a week (days 6, 13, 20, and 27 after CAR T infusion). Serum cytokine levels were measured using the MSD Multi-Spot Assay T-plex Human Cytokine Assay Kit at weeks 1 and 4.
[0279] like Figure 2A-2B As shown, in the low stringency SHP-77 subcutaneous tumor model, 2G1CAR T expressing the 15.1CCR construct outperformed the same CAR T cells expressing the 15.3CCR construct. DLL32G1.15.1CAR ("+15tail.1") exhibited the most durable anti-tumor response than DLL32G1.15.3CAR ("+15tail.3") or the parental CAR without CCR ("2G1-RSR") ( Figure 2A Of the three, the DLL32G1.15.1CAR also showed the highest amount of CAR T cells in the blood after injection, evidence of in vivo persistence ( Figure 2B Similarly, in high-stringency animal models, suboptimal CAR T doses (3x10 6 DLL32G1.15.1CAR is superior to DLL32G1.15.3CAR ( Figure 2C ), although when injected with 6x10 6When the CAR T cells were used per animal (i.e., less stringent conditions), the difference was less obvious. DLL32G1.15.1CAR also showed excellent in vivo persistence ( Figure 2D ) and secrete higher levels of serum cytokines in high-stringency animal models ( Figure 2E ). Since DLL32G1.15.1CAR showed the best activity, CART cells expressing 2G1 CAR and 15.1CCR were used in the following experiments.
[0280] To prepare lentivirus encoding individual DLL3 CAR, DLL3 CAR and CCR and / or chimeric switch receptors, HEK-293T cells were seeded at 0.75 million cells per ml in 2mL DMEM (Gibco) supplemented with 10% FBS (Hyclone) per well of a 6-well plate on day 0. On day 1, lentivirus was prepared by mixing 1.5ug psPAX2, 0.5ug pMD2G, and 0.5ug appropriate CAR vector or chimeric switch receptor vector in 250uL Opti-MEM (Gibco) per well of a 6-well plate ("DNA mixture"). 10uL Lipofectamine2000 (Invitrogen) in 250uL Opti-MEM was incubated at room temperature for 5 minutes and then added to the DNA mixture. The mixture was incubated at room temperature for 20 minutes, and a total volume of 500uL was slowly added to the side of the well containing HEK-293T. Purified T cells were activated in X-Vivo-15 medium (Lonza) supplemented with 100 IU / mL human IL-2 (Miltenyi Biotec), 10% FBS (Hyclone) and human T TransAct (Miltenyi Biotec, catalog number 130-111-160, 1:100 dilution). On day 2, the medium of each well of the 6-well plate was replaced with 2 mL of T cell transduction medium per well (i.e., X-Vivo-15 supplemented with 10% FBS). On day 3, T cells were resuspended in 1 mL of T cell transduction medium per well of a Grex-24 plate (Wilson Wolf, catalog number 80192M) at 0.75 million cells per ml. The lentiviral supernatant of HEK293T cells was collected and passed through a 0.45 micron filter (EMD Millipore) to remove cell debris, then mixed with Lenti-X Concentrator (Clontech) and incubated at 4 ° C for 30 minutes. The mixture was then centrifuged at 1,500xg for 45 minutes at 4 ° C to obtain a precipitate containing high titer virus. After removing the supernatant, the precipitate was resuspended in 1 / 25 of the original volume using T cell transduction medium, and 150ul to 350ul of concentrated virus was added to T cells together with 100IU / mL human IL-2. On the 5th day, 4.5mL T cell expansion medium, i.e., X-Vivo-15 supplemented with 5% human AB serum (Gemini Bio), was added to each well of the Grex-24 plate. On the 9th and 13th days, the CAR transduction efficiency and chimeric switch receptor transduction efficacy were determined.The cells were then cultured for 4 hr by first treating with 1 μg / ml Flag-tagged recombinant DLL3 (Adipogen) in PBS+1% BSA. ℃ T cells were stained for 20 minutes at 4 °C and then stained with PE-labeled anti-Flag antibody (Biolegend, catalog number 637310) to measure CAR transduction. The chimeric switch receptor was determined by first staining the T cells with 10 μg / ml anti-PD1 antibody nivolumab (Selleckchem, catalog number A2002) and then staining with anti-human IgG-APC (Jackson ImmunoResearch) diluted 1:200. T cells were expanded into larger flasks or G-Rex containers (Wilson Wolf) using T cell expansion medium as needed. On day 14 or 16, DLL3 CAR-T cells were cryopreserved. Prior to cryopreservation, the percentage of cells stained with recombinant DLL3 was normalized across clones.
[0281] Figure 2F Experimental data are presented, which show that PD1 chimeric switch receptors are expressed alone or together with DLL3CAR and CCR (2G1.15.1) on the surface of primary T cells. The percentage of T cells expressing one or both of DLL3CAR and chimeric switch receptors was determined by staining with recombinant DLL3 and nivolumab. These figures are gated with live single T cells. Figure 2G Bar graphs summarizing the percentage of T cells transduced with one or both vectors are presented. Figure 2H Experimental data are presented showing that all T cells expanded well during the generation period, with cell numbers increasing approximately 90- to 120-fold from day 2 to day 14.
[0282] Embodiment 3: Cytotoxic activity of DLL3CAR T cells co-transduced with lentivirus expressing or not expressing the chimeric switch receptor
[0283] The cytotoxicity of T cells generated according to the method in Example 2 was determined in a serial killing assay. The serial killing assay involves repeatedly exposing T cells to their target, causing the T cells to undergo proliferation, and in some cases differentiation and exhaustion. The assay is used to select the best clones with high target cell killing and proliferation capabilities after several rounds of exposure to target cells.
[0284] On the first day of the assay, 5,000 firefly luciferase-labeled DMS273 (DLL3 low, PDL1 low) or DMS273-PDL1 (DLL3 low, PDL1 high) cells were seeded in 100ul RPMI medium with 10% FBS in a 96-well plate with white walls and a flat clear bottom. After the target cells attached to the bottom of the plate, T cells expressing the PD1 chimeric switch receptor alone or with the DLL3 CAR were thawed and added to the target cells plated in 100ul RPMI medium with 10% FBS at an effector:target (E:T) ratio of 9:1 or 3:1. Every 2 to 3 days thereafter, 100μl of medium containing T cells was transferred to the newly plated target cells, and the percentage of lysis of the previously plated target cells was determined using the one-glo assay system or the CellTiter-glo system (Promega). Three to six replicates were assayed for each condition. The average percentage of lysis and standard deviation are plotted on Figure 3A and 3B middle. Figure 3A Experimental data from a series of killing assays are presented, showing cytotoxicity of T cells co-expressing DLL3 CAR and PD1 chimeric switch receptor with wild-type PD1 extracellular domain against DMS273 (PDL1 low) or DMS273-PDL1 (PDL1 high) cells. Data for the high-affinity PD1 chimeric switch receptor are presented in Figure 3B DLL3 CAR T cells expressing WT PD1-CD28, WT PD1-CD2 short, HA PD1-CD28 or HA-CD2 short showed activity against DMS 273 cells comparable to or slightly better than DLL3 CAR T cells that did not express the chimeric switch receptor, but showed significantly increased activity against DMS273-PDL1 high target cells, indicating that high levels of PDL1 on DMS273-PDL1 are sufficient to aggregate and induce signaling of the PD1 chimeric switch receptor. T cells expressing the PD1 chimeric switch receptor alone did not show cytotoxicity against any target cells tested (data not shown).
[0285] Embodiment 4: Cytokines secreted by DLL3CAR T cells co-transduced with lentivirus expressing or not expressing the chimeric switch receptor
[0286] The cytokines secreted by T cells produced according to the method in Example 2 were measured using a human pro-inflammatory 9-Plex tissue culture kit (Meso Scale Discovery, 15007B). On the first day of the assay, 5,000 DMS273 (DLL3 low, PDL1 low) or DMS 273-PDL1 (DLL3 low, PDL1 high) cells were seeded in 100ul RPMI medium with 10% FBS in a 96-well plate. After the target cells attached to the bottom of the plate, T cells expressing the PD1 chimeric switch receptor alone or with DLL3 CAR and CCR (2G1.15.1) were thawed and added to the target cells plated in 100ul RPMI medium with 10% FBS at an effector: target (E:T) ratio of 1:1 or 1:1. After 24 hours, the culture medium of the co-culture was collected from each well and centrifuged to precipitate the T cells. The supernatants were then frozen at -80°C and then thawed for cytokine analysis using the Meso Scale Discovery assay according to the manufacturer's protocol.
[0287] Figure 4A-4B Experimental data are presented showing that T cells expressing both DLL3 CAR and CCR (2G1.15.1) together with the PD1 chimeric switch receptor secrete cytokines when co-cultured with DLL3-positive target cells. When T cells were co-cultured with PDL1 low DMS273 cells, all T cells secreted very small amounts of cytokines (IL-2 and IFNγ are shown as representative cytokines) ( Figure 4A When T cells were co-cultured with PDL1 high DMS273-PDL1 cells, PD1 chimeric switch receptors with CD28, CD2, or CD2 short signaling domains showed increased cytokine secretion, with CD28 showing the most significant increase (more than 10-fold) ( Figure 4B When co-cultured with DMS 273-PDL1 cells, all CARTs with PD1 chimeric switch receptors secreted higher levels of IL-2 and IFNγ than CAR T without PD1 chimeric switch receptors ( Figure 4B ).
[0288] Embodiment 5: Generation of DLL3CAR T cells expressing or not expressing chimeric switch receptors using multiple site-specific integration (SSI)
[0289] To generate DLL3 CART cells (or CD70 CAR T cells) expressing or not expressing chimeric switch receptors using multiple site-specific integration (SSI), we first used EasySep TMHuman T Cell Isolation Kit (StemCell) Primary human T cells were purified from LeukoPak (StemCell Technologies).
[0290] On day 0, purified T cells were activated in X-Vivo-15 medium (Lonza) supplemented with 100 IU / mL human IL-2 (Miltenyi Biotec), 10% FBS (Hyclone), and human TTransAct (Miltenyi Biotec, catalog number 130-111-160, 1:100 dilution). On day 2, P3 primary cells were cultured using 4D-Nucleofector TM X kit (Lonza, catalog number V4XP-3024) was used for electroporation with TALEN targeting TRAC and CD52 loci. The activated T cells were pelleted, washed twice with PBS, and electroporated with 100ul of Lonza electroporation buffer (by mixing 18ul of supplement with 4D-Nucleofector from P3 primary cells). TM 82ul Nucleofector for X Kit TM TALEN mRNA targeting TRAC and CD52 loci was added to the resuspended T cells at 10 ug per TALEN mRNA per 10 million cells, and the mixture was loaded into Nucleocucette (Lonza) for use with Amaxa TMElectroporation was performed using the DS115 program (for stimulated human T cells) on a 4D-nucleic acid transfection instrument (Lonza, AAF-1002X). The electroporated T cells were removed from the tubes and plated at 3 million cells per well in a 96-well V-bottom plate with 50ul X-Vivo-15 medium (Lonza) supplemented with 5% human serum (GeminiBio) and 100IU / mL human IL-2 (Miltenyi Biotec). T cells were then transduced with AAV encoding DLL3 CAR (or CD70 CAR) and / or chimeric switch receptors at a multiplicity of infection (MOI) of 5000 to 10,000 and incubated at 30°C for 1 hour. After incubation for 1 hour, the T cells were transferred to a Grex-24 plate (Wilson Wolf, catalog number 80192M) pre-filled with 1 ml of X-Vivo-15 medium (supplemented with 5% human serum and 100 IU / mL human IL-2) and incubated overnight at 30 ° C. On the 3rd day, the Grex-24 plate containing the transduced T cells was moved to a 37 ° C incubator, and 1 ml of X-Vivo-15 medium supplemented with 5% human serum and 100 IU / mL human IL-2 was added to each well. On the 5th day, 6 mL of X-Vivo-15 supplemented with 5% human AB serum and 100 IU / mL human IL-2 was added to each well of the Grex-24 plate. From the 5th day to the day of cell cryopreservation, the cells were split when the density exceeded 5 million per milliliter, and 100 IU / mL human IL-2 was added to the culture medium every 2 to 3 days.
[0291] During the production period, TRAC and CD52 knockout efficiency were determined on the 6th day. CAR (2G1.15.1) transduction efficiency and chimeric switch receptor transduction efficiency were determined on the 6th, 9th and 13 / 14th days. T cells were first stained with 1 μg / mlFlag-tagged recombinant DLL3 (Adipogen) in PBS+1% BSA for 20 minutes at 4°C, and then stained with 3 μg / ml PE-labeled anti-Flag antibody (Biolegend, catalog number 637310) to measure CAR transduction. Chimeric switch receptors were determined by first staining T cells with 10 μg / ml nivolumab (Selleckchem, catalog number A2002) at 4°C for 20 minutes, and then staining with 1:200 diluted anti-human IgG-APC (Jackson ImmunoResearch) at 4°C for 20 minutes. T cells were expanded into larger flasks or G-Rex containers (Wilson Wolf) using T cell expansion medium as needed. DLL3 CAR-T cells (or CD70 CAR T cells) were cryopreserved on day 14 or 16. Prior to cryopreservation, the percentage of cells stained with recombinant DLL3 was normalized across clones.
[0292] Figures 5A-5D Shown is the generation of T cells expressing DLL3 CAR and a chimeric switch receptor from one human T cell donor using SSI. Figure 5A Experimental data showing TALEN-mediated gene knockout efficiency and AAV-mediated transduction efficiency at day 6 of production are shown. Figure 5A The top graph shows that approximately 83% of T cells lost TCRa / b expression, and a subset of TCRa / b-negative T cells expressed DLL3 CAR. Figure 5A The bottom graph shows that approximately 70% of T cells lost CD52 expression, and a subset of CD52-negative T cells expressed the PD1 chimeric switch receptor. Figure 5B Shown are flow cytometry graphs depicting the percentage of T cells expressing DLL3 CAR and / or chimeric switch receptor at generation day 16. These graphs are gated on live single T cells. Figure 5C Bar graphs showing the mean fluorescence intensity of DLL3 CAR (left panel) and PD1 chimeric switch receptor (right panel) are shown. Figure 5D T cell expansion during production is shown.
[0293] Regarding the constructs expressed, dnWT-PD1 (dominant negative wild-type PD1) has the extracellular and TM domains of wild-type PD1, but no intracellular domain. Therefore, it binds to PDL1 (on target cells), thereby competing with endogenous PD1 (on T cells), blocking PDL1 signaling. WT PD1-CD28 or WT or HA PD1-CD2 constructs have the wild-type or high-affinity PD1 extracellular domain and the CD28 or CD2 intracellular domain; therefore, it signals through the intracellular domain after binding to PDL1.
[0294] Figures 6A-6D shows the use of SSI from Figures 5A-5D Different human T cell donors from the donors shown in the generated T cells expressing DLL3 CAR and chimeric switch receptor. Fig. 6A Experimental data showing TALEN-mediated gene knockout efficiency and AAV-mediated transduction efficiency at day 14 of production are shown. Fig. 6A We showed that more than 75% of T cells lost TCRa / b expression and that the majority of TCRa / b-negative T cells expressed DLL3 CAR. Figure 6B showed that the majority of T cells lost CD52 expression and that a subset of CD52-negative T cells expressed the PD1 chimeric switch receptor. Figure 6C Shown are flow cytometry graphs depicting the percentage of T cells expressing DLL3 CAR alone or chimeric switch receptor or both DLL3 CAR and chimeric switch receptor at generation day 14. These graphs are gated on live single T cells. Fig.6D T cell expansion during production is shown.
[0295] Embodiment 6: Cytotoxic activity of T cells expressing chimeric switch receptors using multiple SSI
[0296] In the series of killing assays described in Example 3, DMS273 (DLL3 low, PDL1 low), DMS273-PDL1 (DLL3 low, PDL1 high), DMS273-DLL3 (DLL3 high, PDL1 low) or DMS273-DLL3-PDL1 (DLL3 high, PDL1 high) were used as target cells to determine the cytotoxicity of T cells generated according to the method in Example 5.
[0297] In addition to the serial killing assays described in Example 3, a single-stimulation long-term killing assay was used to evaluate the efficacy of T cell products against high tumor burden. In this assay, different T cell effector activity parameters were examined simultaneously, including target cell killing, CAR T cell expansion, and memory phenotype. On the first day of the assay, 0.25x10 6CAR-T cells were mixed with PDL1 high NCI-H82 cells in 4 mL RPMI medium with 10% FBS at an effector: target ratio of 1:5. Every 2 to 3 days thereafter, 100 ul of the mixed cells were analyzed by flow cytometry. Live target cells (hCD45 - ) and CAR T cells (hCD45 + CAR + Each condition was measured twice.
[0298] Figure 7 Experimental data from a series of killing assays are shown, which show that T cells co-expressing DLL3 CAR and PD1 chimeric switch receptors (with wild-type PD1 ectodomain or high affinity PD1 ectodomain) are cytotoxic against DLL3-positive cells with low or high levels of PD-L1 expression. In the assay, dominant negative PD1 (dnWT PD1) alone did not provide benefit (e.g., did not enhance the cytotoxicity of DLL3CAR T cells), while chimeric switch receptors with intracellular signaling domains from CD28 or CD2 enhanced the activity (e.g., cytotoxicity) of DLL3 CAR T cells.
[0299] Figures 8A-8B Shown are the results of CAR T cells expressing CAR (2G1.15.1) co-expressing an additional PD1 chimeric switch receptor with a different intracellular domain generated by site-specific integration. Fig. 8A The results in the or reporter gene assays showed that the addition of the PD1 chimeric switch receptor also increased the cytotoxic activity compared with CAR T without the PD1 chimeric switch receptor. Fig. 8A The data in showed that multiple PD1 chimeric switch receptors showed enhanced cytotoxic activity compared with control DLL3 CAR T cells, while dominant negative high-affinity PD1 (dnHACiPD1) alone had little effect on enhancing cytotoxicity. Figure 8B In this assay, the target cells were suspension NCI-H82 cells overexpressing PDL1 (with Fig. 8A ) and under stringent conditions (i.e., a low E:T of 1:5 (compared with Fig. 8A Cell killing was performed at an E:T of 9:1 in the presence of 1:1. The remaining target cells and the expansion of CAR T cells were analyzed by flow cytometry. Figure 8BThe data in demonstrate enhanced cytotoxicity of CAR T cells co-expressing several PD1 chimeric switch receptors compared to control CAR T cells, as well as concomitant expansion of CAR-T cells co-expressing different PD1 chimeric switch receptors. Under stringent conditions, CAR T cells with HA PD1 CD28, HA PD1 CD28.YMFM, HA PD1CD28.AYAA, or HAPD1 MyD88 chimeric switch receptors exhibited improved cytotoxicity, whereas CAR T cells with HA PD1 CD2 short chimeric switch receptors performed similarly to control CAR T cells. In cells with high target expression, such as in the case of high DLL3-expressing NCI-H82 cells, the effect of CD2 signaling from the PD1-CD2 chimeric switch receptor may be less pronounced. The superior activity of chimeric switch receptors with the CD28 intracellular domain (e.g., CD28 variants YMFM and AYAA) or the OX40 intracellular domain under stringent experimental conditions is of particular interest. See. Figure 8B .
[0300] Embodiment 7: Cytokine secretion by T cells expressing chimeric switch receptors using multiplex SSI
[0301] Cytokine secretion by T cells generated according to the method in Example 5 was determined using DMS273 cells (DLL3 low, PDL1 low) or DMS273-PDL1 cells (DLL3 low, PDL1 high) as target cells in the mesoscale discovery assay described in Example 4.
[0302] Figures 9A-9BExperimental data are depicted, which show that when co-cultured with DLL3 positive target cells, T cells expressing both DLL3 CAR / CCR (2G1.15.1) and PD1 chimeric switch receptors secrete cytokines. When T cells are co-cultured with PDL1 high DMS273-PDL1 cells, WT PD1-CD2 short and HA PD1-CD2 short chimeric switch receptors (CSR) show higher levels of cytokine secretion (e.g., higher IL-2 secretion and lower degree of IFNγ secretion) than when CAR T cells are co-cultured with PDL1 low DMS273 cells. Under any conditions tested, a single dominant negative PD1 (dnWT PD1) does not increase cytokine secretion. In this assay, cells include a mixture of CAR+ and CAR- cells and a mixture of CSR+ and CSR- cells. At the end of CAR T production, T cells are normalized (by adding NTD cells) to have the same CAR+ cell percentage, but CSR+ cells are not normalized. Since the CAR+% was the same in the samples, it was concluded that DLL3 CAR T cells with the addition of the PD1 chimeric switch receptor (2G1.15.1) secreted more cytokines than the parental CAR T cells without the PD1 switch receptor.
[0303] We next examined cytokine secretion by CAR T cells co-expressing different PD1 chimeric switch receptors when co-cultured with cell lines expressing high or low levels of PDL1 and being either target-positive or -negative ( Fig. 10A ). Fig. 10B Data are presented showing cytokine secretion from CAR T cells expressing a chimeric switch receptor generated by site-specific integration. Data values are Fig. 10C Shown in. When CAR T cells are co-cultured with PDL1 high cells (condition D), many chimeric switch receptors induce higher levels of cytokine secretion than when the same CAR T cells are co-cultured with PDL1 low DMS273 cells (condition C), indicating that higher levels of PDL1 effectively trigger signaling through the PD1 chimeric antigen receptor. HA PD1-CD28 induces very high levels of all tested cytokines, which may lead to serious adverse events in vivo or in patients (e.g., cytokine release syndrome or immune effector cell-related neurotoxicity syndrome). HA PD1-MyD88 also induces very high levels of GM-CSF, which can potentially lead to macrophage activation and toxicity in the clinic. CAR T co-expressing another chimeric switch receptor (e.g., HA PD1CD2 short, HA PD1 CD28.YMFM, HA PD1 CD28.AYAA and HA PD1 OX40 chimeric switch receptor) secretes moderate levels of cytokines and may have better in vivo safety.
[0304] Embodiment 8: Growth factor-independent growth
[0305] To understand whether any chimeric switch receptors lead to aberrant CAR T proliferation, T cells co-expressing DLL3 CAR and PD1 chimeric switch receptor were cultured in the absence of target cells or IL-2 for 6 weeks. 6 CAR-T cells were resuspended in T cell culture medium (RPMI with 10% FBS, 1x non-essential amino acids, 1mM sodium pyruvate, and 25mM HEPES) in a Grex-24 culture container. Every week thereafter, 100ul of cell suspension was analyzed by flow cytometry. The absolute number of viable cells was assessed using 123count eBeads (Thermofisher). Each condition was assayed twice. CAR T cells supplemented with IL-2 (100IU / mL, 2x / week) were used as positive controls. Half of the culture medium was replaced only when the culture medium turned yellow during the assay.
[0306] Fig.11 Data are presented showing expansion of CAR T cells expressing one of the various PD1 chimeric switch receptors in the absence of target cells or growth factors. Total viable cell counts were quantified using flow cytometry. In this assay, HA PD1-MyD88 induced abnormal growth of T cells, which may pose safety concerns. Other chimeric switch receptors behaved similarly to control CAR T or induced only transient, acceptable levels of T cell expansion.
[0307] Example 9 Generation and cytotoxic activity of DLL3 CAR-expressing T cells without a CCR and with or without a chimeric switch receptor
[0308] Next, we generated CAR T cells expressing DLL3 CAR alone without CCR and with or without chimeric switch receptors by LVV transduction or by site-specific integration (as described in Examples 2 and 5 above). The cytotoxic activity of different CAR T cells generated by LVV transduction was analyzed in a long-term killing assay as described in Example 3. Figures 12A-12B As shown in Fig. 12A ) or PDL1 high ( Fig. 12B ) target cells, DLL3 CAR T expressing a high-affinity PD1 chimeric switch receptor with the CD28 YMFM variant intracellular domain outperformed other constructs.
[0309] The CAR T cells generated by site-specific integration were analyzed for cytotoxic activity against PDL1 low or PDL1 high target cells as described in Example 6. For comparison, an inducible chimeric cytokine receptor comprising a TPOR transmembrane domain (TPOR N+4, SEQ ID NO: 177) and a TPOR containing a SEQ ID NO: 4 form ( Fig. 12C ) (as construct iPD1-15.1) or in the form of SEQ ID NO 180 ( Fig. 12C The high-affinity PD1 extracellular domain was fused to the intracellular signaling domain of IL2Rb (as construct iPD1-15.3). When PDL1 low target cells were used, minimal positive effects of the chimeric switch receptor were observed compared to DLL3 CAR T cells that did not co-express the high-affinity PD1 chimeric switch receptor or CAR T cells generated by LVV transduction ( Fig. 12C , results from two different donors). In contrast, when PDL1-high target cells were used, DLL3 CAR T cells expressing the high-affinity PD1 CD28 YMFM chimeric switch receptor outperformed CAR T cells without the chimeric switch receptor or CAR T cells generated by LVV transduction ( Fig.12D , results from two different donors). Of the constructs tested, CAR T cells expressing the high-affinity PD1-switch receptor signaling through the CD28 YMFM intracellular domain showed better activity than constructs signaling through the IL2Rb intracellular signaling domain ( Fig.12D ).
[0310] Example 10 In vitro and in vivo cytotoxicity of CAR T cells co-expressing a chimeric switch receptor
[0311] The PD1 CD28 switch receptor construct was also tested in CAR T cells expressing an exemplary anti-CD70 CAR (SEQ ID NO: 179). CAR T cells were generated by site-specific integration (SSI) as described above in Example 5. Figures 13A-13B As shown, CD70 CAR T cells co-expressing high-affinity PD1 wild-type CD28 or variant CD28 chimeric switch receptors showed modest improvements compared with CD70 CAR T control cells, especially when using PDL1 low or PDL1 high, CD70 high 786O target cells ( Fig.13A ) or PDL1 low or PDL1 high, CD70 low ACHN target cells ( Fig. 13B ) at low E:T ratios.
[0312] The PD1 chimeric switch receptor with the wild-type CD28 intracellular signaling domain elicited stronger cytokine secretion than the variant CD28 intracellular signaling domain ( Figures 10B-10C ). Therefore, a PD1 switch receptor with a variant CD28 signaling domain may be advantageous in providing increased activity in the context of a PD1 chimeric switch receptor with modest cytokine secretion to mitigate any potential safety issues. Next, we tested CD70 CAR T cells co-expressing the PD1-CD28 chimeric switch receptor in a mouse model to evaluate activity and assess toxicity. As described in Example 5, CAR T cells were generated using SSI, in which a bicistronic AAV vector was used to insert the CAR and PD1-CD28 chimeric switch receptor transgenes into the TRAC locus. NOD scid gamma (NSG) mice were subcutaneously implanted with tumor cells 786-O overexpressing PDL1, and once the tumor volume reached 200mm 3 CAR T cells were injected intravenously via the tail vein at a concentration of 1x10 6 Up to 5x10 6 The suboptimal dose of CAR+T cells was used to treat mice to evaluate the benefits of the PD1-CD28 chimeric switch receptor in vivo. Preliminary data showed that mice administered suboptimal low doses of CAR T cells expressing PD1-CD28 wild-type chimeric switch receptors (rather than PD1-CD28 YMFM variant chimeric switch receptors) showed weight loss, although CAR T cell toxicity was not observed in all animals at this low dose (data not shown). The data show that the variant CD28 intracellular domain can bring the benefit of improved in vivo safety.
[0313] All references cited herein, including patents, patent applications, articles, textbooks, etc., and references cited herein, to the extent they have not already been cited, are hereby incorporated by reference in their entirety.
[0314] Although the disclosed teachings have been described with reference to various applications, methods, kits and compositions, it should be understood that various changes and modifications can be made without departing from the teachings herein and the invention as claimed below. The aforementioned examples are provided to better illustrate the disclosed teachings, and are not intended to limit the scope of the teachings presented herein. Although the present teachings have been described according to these exemplary embodiments, it will be readily appreciated by those skilled in the art that many variations and modifications of these exemplary embodiments are possible without excessive experimentation. All such variations and modifications are within the scope of this current teaching.
Claims
1. A polynucleotide encoding a chimeric polypeptide comprising an extracellular domain, a transmembrane domain and one or more intracellular domains, wherein the extracellular domain comprises a PD-1 extracellular domain or a TGFβ receptor extracellular domain or an antibody or an antigen-binding portion thereof that specifically recognizes and binds to PDL1 or TGFb, optionally wherein: (a) the PD-1 extracellular domain comprises the amino acid sequence of SEQ ID NO: 9 or a variant thereof, or (b) the TGFβ receptor extracellular domain comprises the amino acid sequence of SEQ ID NO: 12 or a variant thereof, or (c) the antibody or the antigen-binding portion of the antibody specifically recognizes and binds to PDL1, TGFβ, or any one or more of TGFβ1, TGFβ2 and TGFβ3.
2. The polynucleotide of claim 1, wherein the extracellular domain comprises a PD-1 extracellular domain variant, wherein the PD-1 extracellular domain variant comprises one or more amino acid insertions, deletions and / or substitutions.
3. The polynucleotide of claim 1, wherein the extracellular domain comprises a PD-1 extracellular domain variant, wherein the PD-1 extracellular domain variant comprises the amino acid sequence of SEQ ID NO:
10.
4. The polynucleotide of claim 0, wherein the extracellular domain comprises a TGFβ receptor extracellular domain or a variant thereof.
5. The polynucleotide of claim 0, wherein the extracellular domain comprises the amino acid sequence of SEQ ID NO: 12 or the amino acid sequence of SEQ ID NO:
13.
6. The polynucleotide of claim 0, wherein the extracellular domain comprises an antibody or an antigen-binding portion of an antibody that specifically recognizes and binds to PDL1, TGFβ, or any one or more of TGFβ1, TGFβ2, and TGFβ3.
7. The polynucleotide of claim 0, wherein the extracellular domain comprises a scFv that specifically recognizes and binds to PDL1, TGFβ, or any one or more of TGFβ1, TGFβ2, and TGFβ3.
8. The polynucleotide of claim 0, wherein the extracellular domain comprises a scFv that specifically recognizes and binds to PDL1 or TGFβ1.
9. The polynucleotide of any of the preceding claims, wherein the one or more intracellular domains comprise one or more intracellular signaling domains, optionally wherein the one or more intracellular signaling domains are selected from the group consisting of a CD28 intracellular signaling domain, a CD2 intracellular signaling domain, a MyD88 intracellular signaling domain, an ICOS intracellular signaling domain, a DAP10 intracellular signaling domain, an OX40 intracellular signaling domain, a BAFFR intracellular signaling domain, and a CD40 intracellular signaling domain, any variants thereof, and any combinations thereof.
10. A polynucleotide as described in any of the preceding claims, wherein the one or more intracellular domains comprise the amino acid sequence of one or more of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 31, SEQ ID NO: 35, and any combination thereof.
11. The polynucleotide of any of the preceding claims, wherein the transmembrane domain comprises a CD28 transmembrane domain, a CD2 transmembrane domain, a PD-1 transmembrane domain, an ICOS transmembrane domain, a DAP10 transmembrane domain, an OX40 transmembrane domain, a BAFFR transmembrane domain, or a CD40 transmembrane domain.
12. The polynucleotide of any one of the preceding claims, wherein the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32 or SEQ ID NO:
34.
13. The polynucleotide of any one of the preceding claims, wherein the intracellular domain comprises a variant CD28 intracellular domain, and optionally further wherein the intracellular domain comprises the amino acid sequence of SEQ ID NO: 19 or SEQ ID NO:
20.
14. The polynucleotide of any of the preceding claims, wherein the intracellular domain comprises a CD2 intracellular domain or a variant thereof, optionally further wherein the transmembrane domain comprises a CD2 transmembrane domain.
15. The polynucleotide of any of the preceding claims, wherein the intracellular domain comprises a variant CD2 intracellular domain, wherein the intracellular domain comprises at least one SH3 domain and / or at least one GYF binding domain, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
16. The polynucleotide of claim 15, wherein the SH3 domain comprises the amino acid sequence of SEQ ID NO: 168 or SEQ ID NO: 169, and the GYF binding domain comprises the amino acid sequence of SEQ ID NO:
176.
17. The polynucleotide of claim 15 or 16, wherein the SH3 domain comprises an amino acid sequence of at least one of SEQ ID NOs: 170, 171, 172, 173, 174, 175 and 176.
18. A polynucleotide as described in any of the preceding claims, wherein the intracellular domain comprises a variant CD2 intracellular domain, the variant CD2 intracellular domain comprises the amino acid sequence of SEQ ID NO: 170 and SEQ ID NO: 176, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
19. A polynucleotide as described in any of the preceding claims, wherein the intracellular domain comprises a variant CD2 intracellular domain, the variant CD2 intracellular domain comprises the amino acid sequence of SEQ ID NO: 174 and SEQ ID NO: 175, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
20. A polynucleotide as described in any of the preceding claims, wherein the intracellular domain comprises a variant CD2 intracellular domain, the variant CD2 intracellular domain comprising the amino acid sequence of SEQ ID NO: 170, 171, 173, 174 and 175, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
21. A polynucleotide as described in any of the preceding claims, wherein the intracellular domain comprises a variant CD2 intracellular domain, the variant CD2 intracellular domain comprises the amino acid sequence of SEQ ID NO: 170-176, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
22. The polynucleotide of any of the preceding claims, wherein the intracellular domain comprises a truncated CD2 intracellular domain, wherein the truncated CD2 intracellular domain comprises the amino acid sequence of SEQ ID NO: 24 or an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:
24.
23. The polynucleotide of any of the preceding claims, wherein the intracellular domain comprises a CD2 intracellular domain having the amino acid sequence of SEQ ID NO: 23 or an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:
23.
24. The polynucleotide of any of the preceding claims, wherein the transmembrane domain comprises a CD2 transmembrane domain, optionally wherein the CD2 transmembrane domain comprises the amino acid sequence of SEQ ID NO: 22 or an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:
22.
25. A polynucleotide as described in any of the preceding claims, wherein the polypeptide further comprises a hinge domain located between the extracellular domain and the transmembrane domain, optionally wherein the hinge domain comprises the amino acid sequence of SEQ ID NO: 36 or an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:
36.
26. The polynucleotide of claim 0, wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 75-115 or an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 75-115.
27. The polynucleotide of any one of the preceding claims, wherein the polypeptide further comprises a signal peptide.
28. The polynucleotide of claim 27, wherein the signal peptide comprises a CD8a signal peptide or a TGFb receptor signal peptide, optionally wherein the signal peptide comprises the amino acid sequence of SEQ ID NO: 1 or 2.
29. The polynucleotide of any of the preceding claims, wherein the polynucleotide further encodes a second polypeptide, optionally wherein the second polypeptide comprises a chimeric cytokine receptor (CCR) or a chimeric antigen receptor (CAR).
30. The polynucleotide of claim 29, wherein the CCR is constitutively active or inducible.
31. A vector comprising the polynucleotide of any one of the preceding claims.
32. The vector of claim 31, wherein the vector is a viral vector, optionally wherein the vector is a lentiviral vector.
33. A chimeric polypeptide encoded by the polynucleotide of any one of claims 0-30 or by the vector of claim 31 or 32.
34. A chimeric polypeptide comprising an extracellular domain, a transmembrane domain and one or more intracellular domains, wherein the extracellular domain comprises a PD-1 extracellular domain or a TGFβ receptor extracellular domain or an antibody or an antigen binding portion of an antibody that specifically recognizes and binds to PDL1 or TGFb, optionally wherein: (a) the PD-1 extracellular domain comprises the amino acid sequence of SEQ ID NO: 9 or a variant thereof, or (b) The TGFβ receptor extracellular domain comprises the amino acid sequence of SEQ ID NO: 12 or a variant thereof.
35. The chimeric polypeptide of claim 34, wherein the extracellular domain comprises a PD-1 extracellular domain variant, wherein the PD-1 extracellular domain variant comprises one or more amino acid insertions, deletions and / or substitutions.
36. The chimeric polypeptide of claim 34 or 35, wherein the PD-1 extracellular domain variant comprises the amino acid sequence of SEQ ID NO:
10.
37. The chimeric polypeptide of claim 34, wherein the extracellular domain comprises a TGFβ receptor extracellular domain or a variant thereof.
38. The chimeric polypeptide of claim 37, wherein the extracellular domain comprises the amino acid sequence of SEQ ID NO: 12 or the amino acid sequence of SEQ ID NO:
13.
39. The chimeric polypeptide of any one of claims 34-38, wherein the one or more intracellular domains comprise one or more intracellular signaling domains, optionally wherein the one or more intracellular signaling domains are selected from the group consisting of a CD28 intracellular signaling domain, a CD2 intracellular signaling domain, a MyD88 intracellular signaling domain, an ICOS intracellular signaling domain, a DAP10 intracellular signaling domain, an OX40 intracellular signaling domain, a BAFFR intracellular signaling domain, and a CD40 intracellular signaling domain, any variants thereof, and any combination thereof.
40. The chimeric polypeptide of any one of claims 34-38, wherein the one or more intracellular domains comprise the amino acid sequence of one or more of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 15, SEQ ID NO: 29, SEQ ID NO: 27, SEQ ID NO: 33, SEQ ID NO: 31, SEQ ID NO: 35, and any combination thereof.
41. The chimeric polypeptide of any one of claims 34-40, wherein the transmembrane domain comprises a CD28 transmembrane domain, a CD2 transmembrane domain, a PD-1 transmembrane domain, an ICOS transmembrane domain, a DAP10 transmembrane domain, an OX40 transmembrane domain, a BAFFR transmembrane domain, or a CD40 transmembrane domain.
42. The chimeric polypeptide of any one of claims 34-41, wherein the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 22, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, or SEQ ID NO:
34.
43. The chimeric polypeptide of any one of claims 34-42, wherein the one or more intracellular domains comprise a variant CD28 intracellular domain, and optionally further wherein the variant CD28 intracellular domain comprises the amino acid sequence of SEQ ID NO: 19 or SEQ ID NO:
20.
44. The chimeric polypeptide of any one of claims 34-43, wherein the one or more intracellular domains comprise a CD2 intracellular domain or a variant thereof, optionally further wherein the transmembrane domain comprises a CD2 transmembrane domain.
45. The chimeric polypeptide of any one of claims 34-44, wherein the intracellular domain comprises a variant CD2 intracellular domain, wherein the intracellular domain comprises at least one SH3 domain and / or at least one GYF binding domain, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
46. The chimeric polypeptide of claim 45, wherein the SH3 domain comprises the amino acid sequence of SEQ ID NO: 168 or 169, and the GYF binding domain comprises the amino acid sequence of SEQ ID NO:
176.
47. The chimeric polypeptide of claim 45 or 46, wherein the intracellular domain comprises the amino acid sequence of at least one of SEQ ID NOs: 170, 171, 172, 173, 174, 175 and 176, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
48. The chimeric polypeptide of any one of claims 34-47, wherein the intracellular domain comprises a variant CD2 intracellular domain comprising the amino acid sequence of at least two of SEQ ID NOs: 170-176, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
49. The chimeric polypeptide of any one of claims 34-48, wherein the intracellular domain comprises a variant CD2 intracellular domain comprising the amino acid sequence of SEQ ID NOs: 170 and 176, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
50. The chimeric polypeptide of any one of claims 34-49, wherein the intracellular domain comprises a variant CD2 intracellular domain comprising the amino acid sequence of SEQ ID NOs: 174 and 175, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
51. The chimeric polypeptide of any one of claims 34-50, wherein the intracellular domain comprises a variant CD2 intracellular domain comprising the amino acid sequence of SEQ ID NOs: 170, 171, 173, 174 and 175, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
52. The chimeric polypeptide of any one of claims 34-51, wherein the intracellular domain comprises a variant of a CD2 intracellular domain, the variant of the CD2 intracellular domain comprising the amino acid sequence of SEQ ID NO: 170-176, and optionally the variant CD2 intracellular domain is a truncated CD2 intracellular domain.
53. The chimeric polypeptide of any one of claims 34-52, wherein the one or more intracellular domains comprises a truncated CD2 intracellular domain, wherein the truncated CD2 intracellular domain comprises the amino acid sequence of SEQ ID NO:24 or an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:
24.
54. The chimeric polypeptide of any one of claims 34-53, wherein the one or more intracellular domains comprises a CD2 intracellular domain having the amino acid sequence of SEQ ID NO:23 or an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:
23.
55. The chimeric polypeptide of any one of claims 34-54, wherein the transmembrane domain comprises a CD2 transmembrane domain, optionally wherein the CD2 transmembrane domain comprises the amino acid sequence of SEQ ID NO:22, or an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:
22.
56. The chimeric polypeptide of any one of claims 34-55, wherein the chimeric polypeptide further comprises a signal peptide, optionally a CD8α signal peptide, optionally wherein the signal peptide comprises the amino acid sequence of SEQ ID NO:
1.
57. The chimeric polypeptide of any one of claims 34-56, wherein the polypeptide further comprises a hinge domain located between the extracellular domain and the transmembrane domain, optionally wherein the hinge domain comprises the amino acid sequence of SEQ ID NO: 36, or an amino acid sequence that is at least about 90% identical to the amino acid sequence of SEQ ID NO:
36.
58. The chimeric polypeptide of any one of claims 34-57, wherein the polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 75-115 or an amino acid sequence that is at least 90% identical to any one of SEQ ID NOs: 75-115.
59. The chimeric polypeptide of any one of claims 34-58, wherein the polypeptide further comprises a signal peptide.
60. The chimeric polypeptide of claim 59, wherein the signal peptide comprises a CD8a signal peptide or a TGFb receptor signal peptide, optionally wherein the signal peptide comprises the amino acid sequence of SEQ ID NO: 1 or 2.
61. An engineered immune cell comprising the polynucleotide of any one of claims 0-30.
62. An engineered immune cell comprising the vector of claims 31-32.
63. An engineered immune cell comprising or expressing the chimeric polypeptide of any one of claims 33-60.
64. An engineered immune cell as described in any one of claims 61-63, wherein the cell further comprises or expresses a CAR, wherein the CAR comprises an extracellular ligand binding domain, a transmembrane domain, and an intracellular signaling domain.
65. The engineered immune cell of claim 64, wherein the CAR intracellular signaling domain comprises any one or more of a CD3 ζ signaling domain, a CD28 signaling domain, and a 4-1BB signaling domain.
66. An engineered immune cell as described in claim 64 or claim 65, wherein the CAR extracellular ligand binding domain specifically recognizes / binds to DLL3.
67. The engineered immune cell of any one of claims 61-66, wherein the cell further comprises or expresses a chimeric cytokine receptor (CCR).
68. The engineered immune cell of claim 67, wherein the CCR is constitutively active or inducible.
69. The engineered immune cell of any one of claims 61-68, wherein the chimeric polypeptide comprises an intracellular domain comprising the amino acid sequence of SEQ ID NO: 19 or 24.
70. The engineered immune cell of claim 69, wherein the chimeric polypeptide comprises a PD1 extracellular domain or a variant thereof, wherein the immune cell secretes reduced levels of cytokines compared to an engineered immune cell comprising a chimeric polypeptide comprising a comparable extracellular domain and an intracellular domain comprising an amino acid sequence of SEQ ID NO: 18 or 23, and optionally wherein the reduced level of cytokines is about 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, and 5-fold reduced.
71. An engineered immune cell comprising or expressing a DLL3 CAR and a CCR, wherein the DLL3 CAR comprises the amino acid sequence of SEQ ID NO: 73 or 165, and the CCR comprises the amino acid sequence of SEQ ID NO:
162.
72. The engineered immune cell of claim 71, wherein the engineered immune cell comprises or expresses a polypeptide comprising the amino acid sequence of SEQ ID NO: 74 with or without a signal peptide.
73. An engineered immune cell as described in any one of claims 61-72, wherein the immune cell is a T cell, a tumor infiltrating lymphocyte (TIL), a NK cell, a cell expressing a TCR, a dendritic cell, or a NK-T cell.
74. The engineered immune cell of any one of claims 61-73, wherein the cell is an autologous T cell.
75. The engineered immune cell of any one of claims 61-73, wherein the cell is an allogeneic T cell.
76. A cell population comprising at least about 1 x 10 4 pcs, 1x10 5 pcs, 1x10 6 pcs, 1x10 7 or 1x10 8 A cell according to any one of claims 61-75.
77. A composition comprising the cell of any one of claims 61-75 or the cell population of claim 76 and a pharmaceutically acceptable carrier.
78. A method of treating a disease or condition in a patient comprising administering to the patient a cell as described in any one of claims 61-75, a cell population as described in claim 76, or a composition as described in claim 77.
79. The method of claim 78, wherein the subject is a human and the disorder is cancer.
80. The method of claim 79, wherein the cancer is a hematological malignancy or a solid cancer.
81. The method of claim 80, wherein the cancer is a hematological malignancy, optionally selected from acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), chronic eosinophilic leukemia (CEL), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), and multiple myeloma (MM).
82. The method of claim 80, wherein the cancer is a solid cancer that is bile duct cancer, bladder cancer, bone or soft tissue cancer, brain tumor, breast cancer, cervical cancer, colon cancer, colorectal adenocarcinoma, colorectal cancer, desmoid tumor, embryonal carcinoma, endometrial cancer, esophageal cancer, gastric cancer, gastric adenocarcinoma, glioblastoma multiforme, gynecological tumors, head and neck squamous cell carcinoma, liver cancer, lung cancer, malignant melanoma, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, primary astrocytoma, primary thyroid cancer, prostate cancer, kidney cancer, renal cell carcinoma, rhabdomyosarcoma, skin cancer, soft tissue sarcoma, testicular germ cell tumor, urothelial carcinoma, uterine sarcoma, or uterine cancer.
83. A method for preparing an engineered immune cell, the method comprising the step of introducing the polynucleotide of any one of claims 0-30 or the vector of claim 31 or 32 into an immune cell.
84. The method of claim 83, wherein the polynucleotide or the vector is integrated into the immune cell genome.
85. The method of claim 83 or 84, wherein the vector is a viral vector.
86. The method of any one of claims 83-85, wherein the vector is a lentiviral vector and the polynucleotide or the vector is integrated into the genome by random integration.
87. The method of any one of claims 83-85, wherein the polynucleotide or the vector is integrated into the genome by site-specific integration.
88. The method of claim 87, wherein the polynucleotide or the vector is integrated into one or more of the TRAC locus, the CD52 locus, the CD70 locus, the PD1 locus, the TIM3 locus, the CISH locus, the TIGIT locus, or the cbl-b locus.
89. The method of claim 87 or 88, wherein the polynucleotide or the vector is integrated into the TRAC locus or the CD52 locus.
90. An engineered immune cell prepared by the method of any one of claims 83-89.
Citation Information
Cited By
Chimeric antigen receptor, nucleic acid molecule, CAR-Ms and application thereof
CN120157773A
